

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2026
or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____
Commission File Number: 001-34186

VANDA PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

03-0491827
(I.R.S. Employer
Identification No.)

2200 Pennsylvania Avenue NW, Suite 300E
Washington, DC 20037
(202) 734-3400
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

<u>Title of Each Class</u>	<u>Trading Symbol(s)</u>	<u>Name of Exchange on Which Registered</u>
Common Stock, par value \$0.001 per share	VNDA	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 30, 2026, there were 60,462,687 shares of the registrant’s common stock issued and outstanding.

Vanda Pharmaceuticals Inc.
Quarterly Report on Form 10-Q
For the Quarter Ended June 30, 2026
Table of Contents

	<u>Page</u>
<u>PART I – FINANCIAL INFORMATION</u>	
<u>ITEM 1</u> <u>Financial Statements (Unaudited)</u>	<u>5</u>
<u>Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025</u>	<u>5</u>
<u>Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025</u>	<u>6</u>
<u>Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2026 and 2025</u>	<u>7</u>
<u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended June 30, 2026 and 2025</u>	<u>8</u>
<u>Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025</u>	<u>9</u>
<u>Notes to Condensed Consolidated Financial Statements</u>	<u>10</u>
<u>ITEM 2</u> <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>27</u>
<u>ITEM 3</u> <u>Quantitative and Qualitative Disclosures about Market Risk</u>	<u>39</u>
<u>ITEM 4</u> <u>Controls and Procedures</u>	<u>39</u>
<u>PART II – OTHER INFORMATION</u>	
<u>ITEM 1</u> <u>Legal Proceedings</u>	<u>39</u>
<u>ITEM 1A</u> <u>Risk Factors</u>	<u>39</u>
<u>ITEM 2</u> <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>40</u>
<u>ITEM 3</u> <u>Defaults Upon Senior Securities</u>	<u>40</u>
<u>ITEM 4</u> <u>Mine Safety Disclosures</u>	<u>40</u>
<u>ITEM 5</u> <u>Other Information</u>	<u>40</u>
<u>ITEM 6</u> <u>Exhibits</u>	<u>41</u>
<u>Signatures</u>	<u>42</u>

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q (Quarterly Report) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “goal,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. If the risks, changes in circumstances or uncertainties materialize or the assumptions prove incorrect, the results of Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements in this Quarterly Report may include, but are not limited to, statements about:

- our ability to continue to generate United States (U.S.) sales of Fanapt® (iloperidone) oral tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia;
- our ability to commercialize BYSANTI™ (milsaperidone) for bipolar I disorder and schizophrenia;
- our ability to obtain approval from the U.S. Food and Drug Administration (FDA) for BYSANTI™ for major depressive disorder (MDD);
- our ability to continue to generate sales of HETLIOZ® (tasimelteon) capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in the U.S., in light of existing and potential generic competition, and Europe and HETLIOZ® capsules and oral suspension (HETLIOZ LQ®) for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) in the U.S.;
- our ability to obtain approval from the FDA for HETLIOZ® beyond the currently approved indications;
- our ability to increase market awareness of Non-24 and SMS and market acceptance of HETLIOZ®;
- our ability to continue to generate sales of PONVORY® (ponesimod) tablets for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in the U.S.;
- our ability to obtain approval from the FDA for PONVORY® beyond the currently approved indications;
- our ability to generate sales of NEREUS™ (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
- our ability to obtain approval from the FDA for NEREUS™ for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
- our ability to obtain approval from the FDA for Quimilza™ (imsidolimab) for the treatment of generalized pustular psoriasis;
- our level of success in commercializing our products in new markets;
- our ability to overcome the continued reimbursement and patient access challenges we face as a result of third-party payor coverage;
- our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
- our ability to prepare, file, prosecute, defend and enforce any patent claims and other intellectual property rights;
- our ability to maintain rights to develop and commercialize our products under our license agreements;
- our ability to obtain and maintain regulatory approval of our products and the labeling for any approved products;
- our expectations regarding the timing and success of preclinical studies and clinical trials;
- the safety and efficacy of our products;
- regulatory developments in the U.S., Europe and other jurisdictions;
- limitations on our ability to utilize some or all of our prior net operating losses and orphan drug and research and development credits;
- our expectations regarding the size and growth of the current and potential markets for our products and our ability to serve those markets;

- our expectations regarding trends with respect to our revenues, costs, liabilities and cash, cash equivalents and marketable securities;
- our ability to identify or obtain rights to new products;
- our ability to attract and retain key scientific or management personnel;
- our expectations regarding the cost, time frame, outcome, insurance coverage and effects of any litigation or other dispute;
- our ability to obtain the capital necessary to fund our research and development or commercial activities;
- potential losses incurred from product liability claims made against us; and
- the use of our existing cash, cash equivalents and marketable securities.

All forward-looking statements in this report are expressly qualified in their entirety by the cautionary statements contained throughout this report. We caution you not to rely too heavily on such forward-looking statements. Each forward-looking statement speaks only as of the date of this Quarterly Report, and we undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

We encourage you to read Part I, Item 2, *Management's Discussion and Analysis of Financial Condition and Results of Operations*, and our unaudited condensed consolidated financial statements contained in this Quarterly Report. In addition to the risks described in Part I, Item 1A, *Risk Factors*, of our annual report on Form 10-K (Annual Report) for the fiscal year ended December 31, 2025 and in Part II, Item 1A, *Risk Factors*, of any Quarterly Report filed subsequent to our Annual Report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission from time to time, including on Form 10-Q and Form 8-K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

Part I — FINANCIAL INFORMATION
ITEM 1 Financial Statements (Unaudited)

VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

<i>(in thousands, except for share and per share amounts)</i>	June 30, 2026	December 31, 2025
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 55,882	\$ 84,851
Marketable securities	114,147	178,996
Accounts receivable, net	59,692	54,578
Inventory	1,678	1,852
Prepaid expenses and other current assets	33,085	26,985
Total current assets	264,484	347,262
Property and equipment, net	2,578	2,248
Operating lease right-of-use assets	14,598	3,923
Finance lease right-of-use assets	6,772	7,343
Intangible assets, net	113,115	117,089
Non-current inventory and other	10,920	11,083
Total assets	<u>\$ 412,467</u>	<u>\$ 488,948</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 69,994	\$ 68,297
Product revenue allowances	94,032	76,865
Total current liabilities	164,026	145,162
Operating lease non-current liabilities	15,027	2,991
Finance lease non-current liabilities	3,175	4,076
Other non-current liabilities	10,054	9,533
Total liabilities	192,282	161,762
Commitments and contingencies (Notes 8 and 14)		
Stockholders' equity:		
Preferred stock, \$0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at June 30, 2026 and December 31, 2025	—	—
Common stock, \$0.001 par value; 150,000,000 shares authorized; 60,454,687 and 59,101,630 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	60	59
Additional paid-in capital	725,933	721,264
Accumulated other comprehensive income	38	629
Accumulated deficit	(505,846)	(394,766)
Total stockholders' equity	220,185	327,186
Total liabilities and stockholders' equity	<u>\$ 412,467</u>	<u>\$ 488,948</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
<i>(in thousands, except for share and per share amounts)</i>				
Revenues:				
Net product sales	\$ 50,529	\$ 52,590	\$ 102,247	\$ 102,631
Total revenues	50,529	52,590	102,247	102,631
Operating expenses:				
Cost of goods sold excluding amortization	3,560	2,736	6,719	6,257
Research and development	36,953	21,990	65,388	57,702
Selling, general and administrative	71,838	64,616	140,199	114,700
Intangible asset amortization	1,987	1,751	3,974	3,503
Total operating expenses	114,338	91,093	216,280	182,162
Loss from operations	(63,809)	(38,503)	(114,033)	(79,531)
Other income, net	1,425	3,616	3,225	7,276
Loss before income taxes	(62,384)	(34,887)	(110,808)	(72,255)
Provision (benefit) for income taxes	129	(7,680)	272	(15,554)
Net loss	\$ (62,513)	\$ (27,207)	\$ (111,080)	\$ (56,701)
Net loss per share:				
Basic	\$ (1.04)	\$ (0.46)	\$ (1.86)	\$ (0.96)
Diluted	\$ (1.04)	\$ (0.46)	\$ (1.86)	\$ (0.96)
Weighted average shares outstanding:				
Basic	60,226,570	58,993,990	59,845,391	58,762,358
Diluted	60,226,570	58,993,990	59,845,391	58,762,358

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
<i>(in thousands)</i>				
Net loss	\$ (62,513)	\$ (27,207)	\$ (111,080)	\$ (56,701)
Other comprehensive income (loss):				
Net foreign currency translation gain (loss)	(5)	60	(21)	85
Change in net unrealized gain (loss) on marketable securities	(169)	(69)	(570)	306
Tax benefit (provision) on other comprehensive income (loss)	—	22	—	(69)
Other comprehensive income (loss), net of tax	(174)	13	(591)	322
Comprehensive loss	\$ (62,687)	\$ (27,194)	\$ (111,671)	\$ (56,379)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)

<i>(in thousands, except for share amounts)</i>	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
	Shares	Par Value				
Balances at December 31, 2025	59,101,630	\$ 59	\$ 721,264	\$ 629	\$ (394,766)	\$ 327,186
Issuance of common stock from the exercise of stock options and settlement of equity awards	1,033,432	1	(1)	—	—	—
Stock-based compensation expense	—	—	2,563	—	—	2,563
Net loss	—	—	—	—	(48,567)	(48,567)
Other comprehensive loss, net of tax	—	—	—	(417)	—	(417)
Balances at March 31, 2026	60,135,062	\$ 60	\$ 723,826	\$ 212	\$ (443,333)	\$ 280,765
Issuance of common stock from the exercise of stock options and settlement of equity awards	319,625	—	—	—	—	—
Stock-based compensation expense	—	—	2,107	—	—	2,107
Net loss	—	—	—	—	(62,513)	(62,513)
Other comprehensive loss, net of tax	—	—	—	(174)	—	(174)
Balances at June 30, 2026	60,454,687	\$ 60	\$ 725,933	\$ 38	\$ (505,846)	\$ 220,185

<i>(in thousands, except for share amounts)</i>	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
	Shares	Par Value				
Balances at December 31, 2024	58,310,644	\$ 58	\$ 712,706	\$ 74	\$ (174,292)	\$ 538,546
Issuance of common stock from the exercise of stock options and settlement of equity awards, net of shares withheld for taxes	623,338	1	(916)	—	—	(915)
Stock-based compensation expense	—	—	2,971	—	—	2,971
Net loss	—	—	—	—	(29,494)	(29,494)
Other comprehensive income, net of tax	—	—	—	309	—	309
Balances at March 31, 2025	58,933,982	\$ 59	\$ 714,761	\$ 383	\$ (203,786)	\$ 511,417
Issuance of common stock from the exercise of stock options and settlement of equity awards	146,648	—	—	—	—	—
Stock-based compensation expense	—	—	2,106	—	—	2,106
Net loss	—	—	—	—	(27,207)	(27,207)
Other comprehensive income, net of tax	—	—	—	13	—	13
Balances at June 30, 2025	59,080,630	\$ 59	\$ 716,867	\$ 396	\$ (230,993)	\$ 486,329

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Six Months Ended	
	June 30, 2026	June 30, 2025
<i>(in thousands)</i>		
Cash flows from operating activities		
Net loss	\$ (111,080)	\$ (56,701)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation of property and equipment	540	498
Stock-based compensation	4,670	5,077
Amortization of premiums and accretion of discounts on marketable securities	(176)	(1,302)
Intangible asset amortization	3,974	3,503
Right-of-use asset amortization	2,718	1,716
Deferred income taxes	—	(15,769)
Other non-cash adjustments, net	770	1,171
Changes in operating assets and liabilities:		
Accounts receivable	(5,135)	2,181
Prepaid expenses and other assets	(6,653)	(6,826)
Inventory	197	(2,218)
Accounts payable and other liabilities	11,684	16,966
Product revenue allowances	17,203	3,305
Net cash used in operating activities	(81,288)	(48,399)
Cash flows from investing activities		
Acquisition of intangible asset	(10,000)	—
Purchases of property and equipment	(411)	(735)
Purchases of marketable securities	—	(96,300)
Sales and maturities of marketable securities	64,455	125,667
Net cash provided by investing activities	54,044	28,632
Cash flows from financing activities		
Principal payments on finance leases	(1,632)	(834)
Tax obligations paid in connection with settlement of restricted stock units	—	(915)
Net cash used in financing activities	(1,632)	(1,749)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(93)	183
Net change in cash, cash equivalents and restricted cash	(28,969)	(21,333)
Cash, cash equivalents and restricted cash		
Beginning of period	85,320	102,785
End of period	\$ 56,351	\$ 81,452

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

VANDA PHARMACEUTICALS INC.**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)****1. Business Organization and Presentation*****Business Organization***

Vanda Pharmaceuticals Inc. (the Company or Vanda) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003.

The Company's commercial portfolio is currently comprised of five products: Fanapt® (iloperidone) and BYSANTI™ (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS), PONVORY® (ponesimod) for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease and NEREUS™ (tradipitant) for the prevention of vomiting induced by motion (collectively, the Company's commercial products). In addition, the Company has a number of drugs and/or additional indications for current products in development, including:

- Fanapt® long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension;
- BYSANTI™ for major depressive disorder (MDD);
- HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
- PONVORY® for the treatment of ulcerative colitis and psoriasis;
- Quimilza™ (imsidolimab), an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
- NEREUS™ for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
- VQW-765, a small molecule alpha-7 nicotinic acetylcholine receptor partial agonist, for the treatment of social/performance anxiety and psychiatric disorders;
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and VPO-227 for the treatment of secretory diarrhea disorders, including cholera;
- VTR-297, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of hematologic malignancies and onychomycosis and with potential use as a treatment for several oncology indications; and
- Antisense oligonucleotide (ASO) molecules, including VGA-157A for Parkinson's disease, VCA-894A for the treatment of Charcot-Marie-Tooth Disease, Type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene and VGT-1849A for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy.

Based on the Company's current operating plans, which include continued investment in support of its commercial products, including the ongoing commercial launch of NEREUS™ for the prevention of vomiting induced by motion, which became commercially available in the United States (U.S.) in May 2026, and the upcoming commercial launch of BYSANTI™ for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia, continued clinical development of its commercial and other products, pursuit of regulatory approval of Quimilza™, pursuit of further regulatory approvals for its currently approved products and payments due upon achievement of milestones under its license agreements, the Company believes that its cash, cash equivalents and marketable securities and cash received from product sales will be sufficient for at least the next 12 months as of the date the financial statements were issued. The Company's activities will necessitate significant working capital through 2026 and beyond, and future cash requirements and the adequacy of its available funds will depend on many factors, primarily including the Company's ability to generate revenue, the scope and costs of its commercial, manufacturing and process development activities, including the commercial launches of NEREUS™ and BYSANTI™, a regulatory approval of Quimilza™, the magnitude of its discovery, preclinical and clinical development programs and potential costs to acquire or license the rights to additional products. The Company may need or desire to obtain additional capital to finance its operations through debt, equity or alternative financing arrangements. The Company may also seek capital through collaborations or partnerships with other companies. If the Company is unable to obtain additional financing, it may be required to reduce the scope of its future activities.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with United States generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company's consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended December 31, 2025. The financial information as of June 30, 2026 and for the three and six months ended June 30, 2026 and 2025 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of December 31, 2025 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company's operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.

2. Summary of Significant Accounting Policies

There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates under different assumptions or conditions.

Cash, Cash Equivalents and Restricted Cash

For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for office space leases at the Company's Washington, D.C. headquarters.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025:

<i>(in thousands)</i>	June 30, 2026	June 30, 2025
Cash and cash equivalents	\$ 55,882	\$ 80,983
Restricted cash included in:		
Prepaid expenses and other current assets	103	—
Non-current inventory and other	366	469
Total cash, cash equivalents and restricted cash	<u>\$ 56,351</u>	<u>\$ 81,452</u>

Revenue from Net Product Sales

Net sales by product for the three and six months ended June 30, 2026 and 2025 were as follows:

<i>(in thousands)</i>	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Fanapt® net product sales	\$ 35,989	\$ 29,294	\$ 65,549	\$ 52,839
HETLIOZ® net product sales	5,576	16,192	21,523	37,064
PONVORY® net product sales	7,935	7,104	14,146	12,728
NEREUS™ net product sales	1,029	—	1,029	—
Total net product sales	<u>\$ 50,529</u>	<u>\$ 52,590</u>	<u>\$ 102,247</u>	<u>\$ 102,631</u>

Since the entrance of generic competition in the first quarter of 2023, HETLIOZ® dispenses have decreased. Additionally, inventory levels at the Company's specialty pharmacy customers have been elevated relative to inventory levels prior to the entrance of generic competition. HETLIOZ® net product sales have been and may continue to fluctuate from quarter to quarter depending on when specialty pharmacy customers purchase again. During the second quarter of 2026, there was destocking of inventory by certain of our specialty pharmacy customers, as well as orders that were shipped on June 29, 2026 and arrived on July 1, 2026, both resulting in a decline in volume. These orders that did not arrive by quarter end will be recognized as revenue in the third quarter of 2026. HETLIOZ® net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.

NEREUS™ became commercially available in the U.S. in May 2026. During the second quarter of 2026, there was an initial stocking of NEREUS™ by wholesalers. The Company constrained NEREUS™ net product sales to these wholesaler customers for the three and six months ended June 30, 2026 to an amount not probable of significant revenue reversal due to the uncertainties of patient demand and product returns related to the elevated levels of inventory on hand at these wholesalers.

The Company recognized an increase to net product sales of \$2.9 million and \$4.1 million during the six months ended June 30, 2026 and 2025, respectively, for changes in estimates on variable consideration for performance obligations satisfied in previous periods across the Company's commercial products. The elevated levels of HETLIOZ® inventory have resulted in longer periods to resolve uncertainties related to variable consideration. Furthermore, an amount of variable consideration related to Fanapt® net product sales is subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2025. An amount of variable consideration related to PONVORY® net product sales is also subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2024. The Company's balance of rebates and chargebacks was \$66.4 million and \$63.4 million as of June 30, 2026 and December 31, 2025, respectively. The Company's balance of discounts, returns and other product allowances was \$29.0 million and \$14.7 million as of June 30, 2026 and December 31, 2025, respectively.

Major Customers

Fanapt® and NEREUS™ are available in the U.S. for distribution through a limited number of wholesalers and are also available in retail pharmacies. In addition, NEREUS™ is available by prescription directly through the nereus.us website. HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORY® is available in the U.S. for distribution primarily through a limited number of specialty distributors and specialty pharmacies. The Company invoices and records revenue when its customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., the Company has a distribution agreement for the commercialization of Fanapt® in Israel and sells HETLIOZ® in Germany. There were three major customers that each accounted for more than 10% of total revenues and, as a group, represented 70% of total revenues for the six months ended June 30, 2026. There were three major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 86% of total accounts receivable at June 30, 2026. Receivables are carried at the transaction price paid by wholesalers, specialty pharmacies and specialty distributors, net of estimated prompt-pay discounts and allowance for credit losses. Payment terms differ by customer but are based on customary commercial terms and typically range between thirty and sixty days. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.

Recent Accounting Pronouncements

In November 2024, the Financial Accounting Standards Board (FASB) issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Topic 220-40), which addresses the disaggregation of income statement expenses. This standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements.

3. Marketable Securities

The following is a summary of the Company's available-for-sale marketable securities as of June 30, 2026, which all have contractual maturities of less than two years:

<i>(in thousands)</i>	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Market Value
U.S. Treasury and government agencies	\$ 97,783	\$ 69	\$ (48)	\$ 97,804
Corporate debt	16,360	—	(17)	16,343
Total marketable securities	<u>\$ 114,143</u>	<u>\$ 69</u>	<u>\$ (65)</u>	<u>\$ 114,147</u>

The following is a summary of the Company's available-for-sale marketable securities as of December 31, 2025, which all have contractual maturities of less than two years:

<i>(in thousands)</i>	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Market Value
U.S. Treasury and government agencies	\$ 153,212	\$ 523	\$ —	\$ 153,735
Corporate debt	25,210	51	—	25,261
Total marketable securities	<u>\$ 178,422</u>	<u>\$ 574</u>	<u>\$ —</u>	<u>\$ 178,996</u>

4. Fair Value Measurements

Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

- Level 1 — defined as observable inputs such as quoted prices in active markets
- Level 2 — defined as inputs other than quoted prices in active markets that are either directly or indirectly observable
- Level 3 — defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions

The Company's assets classified in Level 1 and Level 2 as of June 30, 2026 and December 31, 2025 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level 2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper and corporate notes that use as their basis readily observable market parameters.

The Company held certain assets that are required to be measured at fair value on a recurring basis as of June 30, 2026, as follows:

<i>(in thousands)</i>	Total Fair Value	Fair Value Measurement as of June 30, 2026 Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
U.S. Treasury and government agencies	\$ 97,804	\$ 97,804	\$ —	\$ —
Corporate debt	16,343	—	16,343	—
Total assets measured at fair value	<u>\$ 114,147</u>	<u>\$ 97,804</u>	<u>\$ 16,343</u>	<u>\$ —</u>

The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2025, as follows:

(in thousands)	Total Fair Value	Fair Value Measurement as of December 31, 2025 Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
U.S. Treasury and government agencies	\$ 153,735	\$ 153,735	\$ —	\$ —
Corporate debt	25,261	—	25,261	—
Total assets measured at fair value	\$ 178,996	\$ 153,735	\$ 25,261	\$ —

Total assets measured at fair value as of June 30, 2026 and December 31, 2025 include no cash equivalents.

The Company also has financial assets and liabilities not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities and product revenue allowances, the carrying values of which materially approximate their fair values.

5. Inventory

Inventory consisted of the following as of June 30, 2026 and December 31, 2025:

(in thousands)	June 30, 2026	December 31, 2025
Current assets		
Work-in-process	\$ 58	\$ —
Finished goods	1,620	1,852
Total inventory, current	\$ 1,678	\$ 1,852
Non-Current assets		
Raw materials	\$ 934	\$ 934
Work-in-process	5,587	5,996
Finished goods	1,935	2,238
Total inventory, non-current	8,456	9,168
Total inventory	\$ 10,134	\$ 11,020

Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life, taking into account all possible alternative uses for the inventory available in the ordinary course of business. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage and generic competition. The Company's inventory balance consisted of \$7.1 million of HETLIOZ[®] product and \$3.1 million of other products as of June 30, 2026. The Company's inventory balance consisted of \$7.8 million of HETLIOZ[®] product and \$3.2 million of other products as of December 31, 2025.

6. Intangible Assets

HETLIOZ[®]. In January 2014, the United States Food and Drug Administration (FDA) approved the New Drug Application (NDA) for HETLIOZ[®]. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of \$8.0 million to BMS. In April 2018, the Company met its final milestone under its license agreement with BMS when cumulative worldwide sales of HETLIOZ[®] reached \$250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of \$25.0 million in 2018. These milestone payments were determined to be additional consideration for the acquisition of HETLIOZ[®] and capitalized as an intangible asset and are being amortized on a straight-line basis over the estimated economic useful life of the related product patents.

PONVORY[®]. In December 2023, the Company acquired the U.S. and Canadian rights to PONVORY[®] from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. The total purchase price of \$104.9 million, \$100.7 million of which was paid in 2023 and the remaining \$4.2 million in 2024, was allocated to the acquired intangible asset for the U.S. and

Canadian rights to PONVORY®. The PONVORY® intangible asset is being amortized on a straight-line basis over the estimated economic useful life of the related product rights.

NEREUS™. In December 2025, the FDA approved the NDA for NEREUS™. As a result of this approval, the Company met a milestone under its license agreement with Eli Lilly and Company (Lilly) that required the Company to make a license payment of \$10.0 million to Lilly, which was accrued in the Company's Consolidated Balance Sheets as of December 31, 2025 and represented a non-cash investing activity for the year ended December 31, 2025, and was paid in the first quarter of 2026. This milestone obligation was determined to be additional consideration for the acquisition of NEREUS™ and capitalized as an intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents.

The following is a summary of the Company's amortizing intangible assets as of June 30, 2026:

(in thousands)	Estimated Useful Life	June 30, 2026		
		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
HETLIOZ®	2035	\$ 33,000	\$ 19,593	\$ 13,407
PONVORY®	2042	104,894	14,714	90,180
NEREUS™	2036	10,000	472	9,528
Total amortizing intangible assets		<u>\$ 147,894</u>	<u>\$ 34,779</u>	<u>\$ 113,115</u>

The following is a summary of the Company's amortizing intangible assets as of December 31, 2025:

(in thousands)	Estimated Useful Life	December 31, 2025		
		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
HETLIOZ®	2035	\$ 33,000	\$ 18,863	\$ 14,137
PONVORY®	2042	104,894	11,942	92,952
NEREUS™	2036	10,000	—	10,000
Total amortizing intangible assets		<u>\$ 147,894</u>	<u>\$ 30,805</u>	<u>\$ 117,089</u>

As of June 30, 2026 and December 31, 2025, the Company also had \$27.9 million of fully amortized intangible assets related to Fanapt®.

Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense was \$2.0 million and \$1.8 million for the three months ended June 30, 2026 and 2025, respectively. Amortization expense was \$4.0 million and \$3.5 million for the six months ended June 30, 2026 and 2025, respectively.

The following is a summary of the future intangible asset amortization schedule as of June 30, 2026:

(in thousands)	Total	2026	2027	2028	2029	2030	Thereafter
HETLIOZ®	\$ 13,407	\$ 731	\$ 1,463	\$ 1,463	\$ 1,463	\$ 1,463	\$ 6,824
PONVORY®	90,180	2,772	5,544	5,544	5,544	5,544	65,232
NEREUS™	9,528	471	941	941	941	941	5,293
Total amortization expense	<u>\$ 113,115</u>	<u>\$ 3,974</u>	<u>\$ 7,948</u>	<u>\$ 7,948</u>	<u>\$ 7,948</u>	<u>\$ 7,948</u>	<u>\$ 77,349</u>

7. Accounts Payable and Accrued Liabilities

The following is a summary of the Company's accounts payable and accrued liabilities as of June 30, 2026 and December 31, 2025:

<i>(in thousands)</i>	June 30, 2026	December 31, 2025
Research and development expenses	\$ 25,086	\$ 18,917
Professional fees	21,206	16,506
Compensation and employee benefits	8,116	10,322
Finance lease liabilities	4,005	3,403
Royalties payable	2,273	2,057
Operating lease liabilities	625	2,152
Milestone obligations under license agreements	—	10,000
Accounts payable and other accrued liabilities	8,683	4,940
Total accounts payable and accrued liabilities	<u>\$ 69,994</u>	<u>\$ 68,297</u>

8. Commitments and Contingencies

Guarantees and Indemnifications

The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company's business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company's products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.

License Agreements

The Company's rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.

Fanapt®. Pursuant to the terms of a settlement agreement with Novartis Pharma AG (Novartis), Novartis transferred all U.S. and Canadian rights in the Fanapt® franchise to the Company on December 31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt® net sales equal to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the new chemical entity patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026.

HETLIOZ®. In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ®. As of June 30, 2026, the Company has paid BMS \$37.5 million in upfront fees and milestone obligations, including \$33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 6, *Intangible Assets*). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ® net sales to BMS in each territory where the Company commercializes HETLIOZ® for a period of 10 years following the first commercial sale in the territory. The royalty is 5% on net sales in territories outside the U.S. The Company's obligation to pay royalties in the U.S. ended in April 2024. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. The Company is obligated to use commercially reasonable efforts to develop and commercialize HETLIOZ®.

NEREUS™. In April 2012, the Company entered into a license agreement with Lilly under which it acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS™ for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered royalties on net sales at

percentage rates up to the low double digits. As of June 30, 2026, the Company has paid Lilly \$15.0 million in upfront fees and development milestones, including a \$10.0 million milestone paid to Lilly during the first quarter of 2026 for the FDA's approval of the Company's NDA for the prevention of vomiting induced by motion in the fourth quarter of 2025, which was accrued as a current liability on the Consolidated Balance Sheets as of December 31, 2025. As of June 30, 2026, remaining milestone obligations include a \$5.0 million milestone for the first approval of an application for marketing authorization for NEREUSTM in the E.U. and up to \$80.0 million for sales milestones. The Company is obligated to use commercially reasonable efforts to develop and commercialize NEREUSTM.

QuimilzaTM. In January 2025, the Company entered into an exclusive global license agreement with AnaptysBio, Inc. (Anaptys) under which it acquired the worldwide rights to develop, manufacture and commercialize QuimilzaTM. Under the terms of the agreement, which was accounted for as an asset acquisition, the Company made an upfront payment of \$10.0 million to Anaptys and an additional \$5.0 million payment for drug supply, \$14.4 million of which was included in research and development expense on the Consolidated Statements of Operations for the year ended December 31, 2025. Anaptys is eligible to receive future payments based upon achievement of specified regulatory approval and commercialization milestones, as well as a 10% royalty on global net sales. As of June 30, 2026, remaining milestone obligations include up to \$35.0 million for future regulatory approval and sales milestones, including \$5.0 million each for the first approval of an application for marketing authorization for QuimilzaTM in the U.S. and E.U. and \$25.0 million for a sales milestone. The Company is obligated to use commercially reasonable efforts to develop and commercialize QuimilzaTM.

Portfolio of CFTR activators and inhibitors. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which it acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. As of June 30, 2026, the Company has paid UCSF \$1.8 million in upfront fees and development milestones. As of June 30, 2026, remaining milestone obligations include \$11.9 million for development milestones and \$33.0 million for future regulatory approval and sales milestones. Included in the \$11.9 million of development milestones are \$1.1 million of milestone obligations due upon the conclusion of clinical studies for each licensed product, not to exceed \$3.2 million in total for the CFTR portfolio.

VQW-765. In connection with a settlement agreement with Novartis relating to Fanapt[®], the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations, but Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.

Other Agreements

Olipass. In September 2022, the Company entered into an agreement with OliPass Corporation (OliPass) to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids. As consideration for entering into the arrangement, the Company paid OliPass an upfront fee of \$3.0 million, which was recorded as research and development expense in 2022. Under the agreement, the Company held an option to license jointly developed intellectual property upon successful development. In May 2026, the Company elected not to exercise the option.

Clinical Trial Agreement. In December 2024, the Company entered into an agreement with a third party to jointly design and complete a pediatric study for PONVORY[®] required by the FDA and the European Medicines Agency. Pursuant to the agreement, the Company will bear the primary responsibility for completing the clinical trial, and the third party will bear primary responsibility for manufacturing the clinical study product. All costs associated with the pediatric study will be shared equally by the Company and the third party. As the Company and the third party are both active participants in the research activities and both parties are exposed to significant risks and rewards, the agreement is being accounted for under Accounting Standards Codification (ASC) 808. Furthermore, no parts of the agreement are within the scope of ASC 606, because the Company determined that performing research and development activities on behalf of other parties is not part of the ordinary activities of its business. Therefore, reimbursements from the third party for research and development costs are recorded as reductions to research and development expense as incurred. Expenses recognized by the Company related to activities under the collaborative arrangement, which commenced during the first quarter of 2025, were \$1.2 million and \$2.0 million for the three and six months ended June 30, 2026, respectively, which were reduced by amounts reimbursable from the third party of \$0.5 million and \$0.8 million, respectively. Expenses recognized by the Company related to activities under the collaborative arrangement were not material for the three and six months ended June 30, 2025.

Lease Agreements. In May 2026, the Company entered into an amendment to the operating lease for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The amendment extended the term of the lease from July 2028 to July 2038, among other terms. The Company has the right to renew the lease for five years following its amended expiration date in July 2038. As of June 30, 2026, the renewal period has not been included in the lease term. As a result of this amendment, the Company reassessed the classification of the lease, determining it remains an operating lease, and remeasured the operating lease right-of-use asset and liability balances using an updated discount rate, resulting in the capitalization of \$9.9 million in its Condensed Consolidated Balance Sheets during the six months ended June 30, 2026.

In August 2024, the Company entered into a master lease agreement for vehicles to be utilized by the Company's sales force. The individual car leases commence upon delivery of the vehicles. Delivery of these vehicles began in the fourth quarter of 2024, and they were determined to be finance leases upon lease commencement. The contractual period of each lease is three years. The Company continues to lease additional cars under the master lease agreement. The Company capitalized \$1.1 million and \$1.2 million for car leases that commenced during the six months ended June 30, 2026 and 2025, respectively, all of which were determined to be finance leases. Total fixed payments for the vehicle leases that had not yet commenced as of June 30, 2026 are estimated to be \$0.2 million, payable over initial terms of three years, and subject to change upon finalization of each vehicle lease contract.

For further information regarding the Company's lease agreements, see Note 8, *Leases*, to the consolidated financial statements included in the Company's Annual Report for the fiscal year ended December 31, 2025.

Purchase Commitments

In the normal course of its business, the Company regularly enters into agreements with third-party vendors under fee service arrangements, which generally may be terminated on 90 days' notice without incurring additional charges, other than charges for work completed or materials procured but not paid for through the effective date of termination and other costs incurred by the Company's contractors in closing out work in progress as of the effective date of termination. Occasionally, the Company enters into short- and long-term agreements with third-party vendors that are non-cancellable. Our short-term non-cancellable purchase commitments primarily relate to inventory and clinical manufacturing purchase commitments, for which the production is expected to be completed within a one-year period, and certain marketing activities. The Company's unrecognized non-cancellable purchase commitments for agreements with a remaining non-cancellable term longer than one year from June 30, 2026 primarily relate to commitments for marketing activities, inventory purchase commitments for certain of the Company's commercial products and data services, of which \$6.3 million, \$14.0 million, \$7.4 million and \$2.6 million are expected to be paid in 2026, 2027, 2028 and 2029, respectively. Various other long-term agreements entered into for services with other third-party vendors are cancellable in nature or contain variable commitment terms within the agreement that are within the Company's control.

9. Accumulated Other Comprehensive Income

The accumulated balances related to each component of other comprehensive income, net of taxes, were as follows as of June 30, 2026 and December 31, 2025:

<i>(in thousands)</i>	June 30, 2026	December 31, 2025
Foreign currency translation	\$ 47	\$ 68
Unrealized gain (loss) on marketable securities	(9)	561
Accumulated other comprehensive income	<u>\$ 38</u>	<u>\$ 629</u>

10. Stock-Based Compensation

As of June 30, 2026, there were 8,542,710 shares subject to outstanding options, restricted stock units (RSUs) and performance restricted stock units (PSUs) under the Amended and Restated 2016 Equity Incentive Plan (2016 Plan). No awards remain in effect under the 2006 Equity Incentive Plan (2006 Plan, and together with the 2016 Plan, Plans), which expired by its terms in April 2016. In June 2016, the Company's stockholders approved the 2016 Plan. The 2016 Plan has been amended a number of times since to increase the number of shares reserved for issuance, among other administrative changes, including, but not limited to, an amendment to eliminate its term. Each of the amendments to the 2016 Plan was approved by the Company's stockholders. There is a total of 20,690,000 shares of common stock authorized for issuance under the 2016 Plan, 5,704,840 shares of which remained available for future grant as of June 30, 2026.

Stock Options

The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors, upon their election, vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Service option awards granted to executive officers and certain other employees provide for partial acceleration of vesting if the executive officer or employee is subject to an involuntary termination, and full acceleration of vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability.

As of June 30, 2026, \$0.4 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 0.4 years. No option awards are classified as a liability as of June 30, 2026.

A summary of option activity under the Plans for the six months ended June 30, 2026 follows:

<i>(in thousands, except for share and per share amounts)</i>	Number of Shares	Weighted Average Exercise Price at Grant Date	Weighted Average Remaining Term (Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2025	4,490,324	\$ 12.75	4.74	\$ 2,698
Forfeited	(17,762)	7.05		
Expired	(297,330)	8.09		
Outstanding at June 30, 2026	4,175,232	13.10	4.56	136
Exercisable at June 30, 2026	4,057,908	13.28	4.50	136
Vested and expected to vest at June 30, 2026	4,174,450	13.11	4.56	136

There were no options granted during the six months ended June 30, 2026 and 2025. There were no options exercised for the six months ended June 30, 2026 and 2025.

Restricted Stock Units

An RSU is a stock award that entitles the holder to receive shares of the Company's common stock as the award vests. The fair value of each RSU is based on the closing price of the Company's stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees and new directors, upon their election, vest in four equal annual installments. Subsequent annual service RSUs granted to directors vest on the first anniversary of the date of grant. Service RSUs granted to executive officers and certain other employees provide for accelerated vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control. Service RSUs granted to directors provide for accelerated vesting if there is a change in control of the Company.

As of June 30, 2026, \$19.5 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.9 years. No RSUs are classified as a liability as of June 30, 2026.

A summary of RSU activity for the 2016 Plan for the six months ended June 30, 2026 is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested at December 31, 2025	3,476,509	\$ 4.99
Granted	2,183,701	6.10
Forfeited	(304,675)	5.19
Vested	(1,353,057)	5.50
Unvested at June 30, 2026	4,002,478	5.41

The total fair value of the 1,353,057 RSUs that vested during the six months ended June 30, 2026 was \$7.4 million.

Performance Restricted Stock Units

In the first quarter of 2026, the compensation committee of the board of directors granted PSUs under the 2016 Plan to the Company's executive officers. The PSUs entitle each employee to earn a number of shares of the Company's common stock ranging from 0% to 150% of the target number of PSUs granted, based on the Company's Total Shareholder Return (TSR) relative to the TSR of the companies comprising the Nasdaq Biotechnology Index (Relative TSR), over the three-year performance period beginning on December 31, 2025 and ending on December 31, 2028 (the Performance Period), subject to the executive's continued employment through the compensation committee of the board of director's certification of performance following the end of the Performance Period. Following the end of the Performance Period, the compensation committee of the board of directors will determine the extent to which the applicable performance goals have been achieved and will determine the number of PSUs, if any, that have been earned, and any such earned PSUs will vest on March 1, 2029. The PSUs provide for accelerated vesting in certain scenarios, including in the event that the executive is subject to an involuntary termination within 24 months after a change in control.

As of June 30, 2026, \$2.7 million of unrecognized compensation costs related to unvested PSUs are expected to be recognized over a weighted average period of 2.7 years. No PSUs are classified as a liability as of June 30, 2026.

A summary of PSU activity for the 2016 Plan for the six months ended June 30, 2026, based on award at target, is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested at December 31, 2025	—	\$ —
Granted	405,000	8.03
Forfeited	(40,000)	8.03
Unvested at June 30, 2026	<u>365,000</u>	<u>8.03</u>

No PSUs vested during the six months ended June 30, 2026.

Stock-Based Compensation Expense

Stock-based compensation expense recognized for the three and six months ended June 30, 2026 and 2025 was comprised of the following:

(in thousands)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Research and development	\$ 583	\$ 596	\$ 1,184	\$ 1,361
Selling, general and administrative	1,524	1,510	3,486	3,716
Total stock-based compensation expense	<u>\$ 2,107</u>	<u>\$ 2,106</u>	<u>\$ 4,670</u>	<u>\$ 5,077</u>

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Expected volatility rates are based on the historical volatility of the Company's publicly traded common stock and other factors. The expected terms are determined based on a combination of historical exercise data and hypothetical exercise data for unexercised stock options. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. There were no options granted during the six months ended June 30, 2026 and 2025.

The fair value of each PSU is estimated on the date of grant using a Monte Carlo model because the performance target is based on a market condition. Expense related to these PSUs is recognized ratably over the three-year measurement period. The expected volatility rate is based on the historical volatility of the Company's publicly traded common stock and other factors. The expected term is determined based on the remaining performance period of the award. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the PSUs in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Monte Carlo model for PSUs granted during the six months ended June 30, 2026 were as follows:

	Six Months Ended
	June 30, 2026
Expected dividend yield	— %
Expected volatility of the Company	61 %
Remaining performance period (years)	2.87
Risk-free rate	3.44 %

11. Income Taxes

The Company assesses the need for a valuation allowance against its deferred tax assets each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After considering all available positive and negative evidence, including but not limited to historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company has concluded that it is not more likely than not that substantially all of its deferred tax assets are realizable in future periods and maintained a valuation allowance against all net deferred tax assets as of June 30, 2026 and December 31, 2025. The valuation allowance was recorded in the fourth quarter of 2025, resulting in a non-cash income tax expense of \$113.7 million for the year ended December 31, 2025.

As a result of the valuation allowance against the Company's deferred tax assets, the Company recognized an income tax provision of \$0.1 million and \$0.3 million for the three and six months ended June 30, 2026, respectively, related to discrete income tax expense. The income tax benefit of \$7.7 million and \$15.6 million for the three and six months ended June 30, 2025 was primarily driven by the estimated effective tax rate for the year, as well as discrete income tax expense of \$0.4 million and \$0.8 million, respectively.

12. Earnings per Share

Basic earnings per share (EPS) is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net loss by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs and PSUs, but only to the extent that their inclusion is dilutive, as calculated using the treasury stock method.

The following table presents the calculation of basic and diluted net loss per share of common stock for the three and six months ended June 30, 2026 and 2025:

	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
<i>(in thousands, except for share and per share amounts)</i>				
Numerator:				
Net loss	\$ (62,513)	\$ (27,207)	\$ (111,080)	\$ (56,701)
Denominator:				
Weighted average shares outstanding, basic and diluted	60,226,570	58,993,990	59,845,391	58,762,358
Net loss per share, basic and diluted	\$ (1.04)	\$ (0.46)	\$ (1.86)	\$ (0.96)
Antidilutive securities excluded from calculations of diluted net loss per share	5,498,144	6,589,315	5,960,663	6,548,565

The Company incurred a net loss for the three and six months ended June 30, 2026 and 2025, causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.

13. Segments

The Company operates in one reportable segment, which includes all activities related to the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The determination of a single reportable segment is consistent with the consolidated financial information regularly provided to the Company's chief operating decision maker (CODM), which is its president, chief executive officer and chairman of the board,

who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. The measure of segment assets is reported on the balance sheet as total assets.

The following table presents the segment revenue and significant expense categories included within the product segment's measure of profit or loss for the three and six months ended June 30, 2026 and 2025:

(in thousands)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Revenue	\$ 50,529	\$ 52,590	\$ 102,247	\$ 102,631
Less:				
Cost of goods sold excluding amortization	3,560	2,736	6,719	6,257
Research and development	36,953	21,990	65,388	57,702
Selling, general and administrative	71,838	64,616	140,199	114,700
Intangible asset amortization	1,987	1,751	3,974	3,503
Other income, net	(1,425)	(3,616)	(3,225)	(7,276)
Provision (benefit) for income taxes	129	(7,680)	272	(15,554)
Net loss	<u>\$ (62,513)</u>	<u>\$ (27,207)</u>	<u>\$ (111,080)</u>	<u>\$ (56,701)</u>

14. Legal Matters

The Company is, from time to time, a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued. However, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it is determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. In other instances, because of the uncertainties related to either the probable outcome or the amount or range of loss, the Company is unable to make a reasonable estimate of a liability.

HETLIOZ®. In December 2022, the Company filed patent infringement lawsuits, including Hatch-Waxman Act claims, against each of Teva Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. and Apotex Corp. (Apotex) in the U.S. District Court for the District of New Jersey (NJ District Court) asserting that U.S. Patent No. 11,285,129 ('129 Patent), will be infringed by Teva's and Apotex' generic versions of HETLIOZ®, each of which was approved by the FDA. The Company asked the NJ District Court to, among other things, order that the effective date of the FDA's approval of Teva's and Apotex' generic versions of HETLIOZ® be a date that is no earlier than the expiration of the '129 Patent, or such later date that the NJ District Court may determine, and enjoin each of Teva and Apotex from the commercial manufacture, use, import, offer for sale and/or sale of their generic versions of HETLIOZ® until the expiration of the '129 Patent, or such later date that the NJ District Court may determine. In February 2023, the case was transferred to the U.S. District Court for the District of Delaware (Delaware District Court). In April 2023, Teva and Apotex moved for judgment on the pleadings. In June 2024, the Delaware District Court denied those motions, allowing the Company's lawsuit to proceed. In March 2025, the Delaware District Court held a claim construction hearing, which resolved two claim term disputes in the Company's favor and deferred ruling on a third dispute between the parties. In May 2025, the Delaware District Court consolidated this action with the Company's action relating to the '556 Patent (as defined below). In March 2026, the Delaware District Court held a hearing on the Company's and Teva's and Apotex's summary judgment and *Daubert* motion. The Company's lawsuit remains pending, and a trial is scheduled to begin on October 26, 2026.

In January 2023, the Company filed a lawsuit in the U.S. District Court for the District of Columbia (DC District Court) against the FDA challenging the FDA's approval of Teva's Abbreviated New Drug Application (ANDA) for its generic version of HETLIOZ® capsules under the Administrative Procedure Act (APA), the Food, Drug, and Cosmetic Act (FDCA), and FDA regulations. Under the FDCA, every ANDA must contain information to show that the labeling proposed for the generic drug is the same as the labeling approved for the listed drug. The labeling and packaging for HETLIOZ® includes Braille, but Teva's generic version does not. On this basis, the Company believes that Teva's approved labeling does not comply with applicable requirements. The Company has asked the DC District Court to, among other things, vacate the FDA's approval of Teva's ANDA, declare that the approval of the ANDA was unlawful, arbitrary, and capricious and compel the FDA to order Teva to recall its generic HETLIOZ® product. In February 2023, Teva intervened in the lawsuit as a defendant. In September 2023, the Company amended its lawsuit to request that the DC District Court set aside the FDA's July 2023 denial of the Company's

citizen petition, originally filed with the FDA in January 2023. In April 2024, the Company filed a motion for summary judgment. In February 2025, the DC District Court denied the Company's motion and granted the FDA and Teva's cross motions for summary judgment. In February 2025, the Company appealed to the U.S. Court of Appeals for the District of Columbia Circuit (DC Circuit). In October 2025, the DC Circuit granted the FDA's motion for a stay of the briefing schedule that it filed in October 2025 due to the government shutdown, and the stay was lifted in November 2025. An oral argument was held on March 12, 2026.

In September 2023, the Company filed a lawsuit in the DC District Court against the FDA challenging the FDA's approval of an ANDA filed by MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) for its generic version of HETLIOZ[®] capsules under the APA, the FDCA, FDA regulations and the Appointments Clause of the U.S. Constitution. The Company believes that MSN's underlying approval data, particularly its bioequivalence studies, are faulty. On this basis, the Company asked the DC District Court to, among other things, vacate the FDA's approval of MSN's ANDA, declare that the approval of the ANDA was unlawful, arbitrary, and capricious, is unconstitutional under the Appointments Clause, and compel the FDA to order MSN to recall its generic HETLIOZ[®] product. In December 2023, the Company filed a motion for summary judgment. In January 2024, the FDA opposed the Company's motion and moved to waive the administrative record, following which the court held an oral argument on the cross-motions. The DC District Court issued an order compelling the FDA to serve the administrative record and set deadlines for further proceedings. In April 2024, the Company filed a motion for summary judgment. In July 2024, the DC District Court held an oral argument on the motion to dismiss that the FDA filed in January 2024, which the Company opposed in February 2024. In September 2024, the DC District Court granted in part the FDA's motion to dismiss as to the Company's APA claims and denied the FDA's motion to dismiss as to the Company's claims under the Appointments Clause. In August 2025, the Company filed a motion for summary judgment based on its Appointments Clause claims, to which the FDA filed an opposition and cross-motion for summary judgment in September 2025. In January 2026, the DC District Court denied the cross-motions for summary judgment without prejudice and stayed the case pending resolution of an agency appeal. In February 2026, the agency denied further review. The Company filed an amended and supplemental complaint in April 2026 continuing to challenge the FDA's approval of the MSN ANDA, challenging the FDA's approval of the ANDA filed by Teva for its generic version of HETLIOZ[®] capsules under the APA, the FDCA, FDA regulations and the Appointments Clause of the U.S. Constitution, challenging the FDA's denial of the Company's citizen petitions requesting revocation of these ANDAs due to their bioequivalence showings and challenging the FDA's denials of further requests for review within the agency. In May 2026, Teva intervened in the lawsuit as a defendant. In June 2026, the Company filed a motion for summary judgment. The Company's lawsuit remains pending.

In April 2024, the Company filed a lawsuit in the Delaware District Court against MSN and its commercial partner Amneal Pharmaceuticals, Inc. (Amneal), and Impax Laboratories LLC (Impax) alleging claims for false advertising in violation of the Lanham Act and unfair competition under several state laws as well as claims for breach of express representation and fraudulent inducement of a license agreement. In July 2024, the defendants filed a motion to dismiss and in September 2024, the Company opposed the motion, to which the defendants replied in October 2024. In July 2025, the Delaware District Court issued its report and recommendation to deny the defendants' motion to dismiss as to standing but granted their motion to dismiss the Lanham Act claims, to which the Company objected in August 2025. In September 2025, the Delaware District Court overruled the Company's objections. In October 2025, the Company appealed the Delaware District Court's decision. The Company's lawsuit remains pending and an oral argument is scheduled for September 29, 2026.

In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ[®], each of which was approved by the FDA. The Company has asked the Delaware District Court to, among other things, order that the effective date of the FDA's approval of Teva's and Apotex' generic versions of HETLIOZ[®] be a date that is no earlier than the expiration of the '556 Patent, or such later date that the Delaware District Court may determine, and enjoin each of Teva and Apotex from the commercial manufacture, use, import, offer for sale and/or sale of their generic versions of HETLIOZ[®] until the expiration of the '556 Patent, or such later date that the Delaware District Court may determine. In March 2025, Teva filed its answer and asserted counterclaims against the Company, including, among other things, for alleged violation of the antitrust laws and inequitable conduct, which the Company opposed in May 2025. The Delaware District Court declined to consolidate this action with the Company's case alleging Lanham Act violations against Teva but consolidated this action with the Company's action relating to the '129 Patent. In March 2026, the Delaware District Court held a hearing on the Company's and Teva's and Apotex's summary judgment and *Daubert* motion. The Company's lawsuit remains pending, and a trial is scheduled to begin on October 26, 2026.

HETLIOZ LQ[®]. In July 2024, the Company filed a Hatch-Waxman lawsuit against MSN in the Delaware District Court asserting that U.S. Patent Nos. 10,179,119, 11,266,622, 11,285,129, 11,850,229, 10,610,510, 10,980,770, and 11,759,446 will be infringed by MSN's generic version of HETLIOZ LQ[®] for which MSN is seeking FDA approval. In June 2025, the

Company filed an amended complaint against MSN, further alleging that U.S. Patent Nos. 10,071,977, 11,566,011 and 11,918,556 (all asserted HETLIOZ LQ[®] patents together, the Asserted Patents) will also be infringed by MSN's generic version of HETLIOZ LQ[®]. The Company has asked the Delaware District Court to, among other things, enter judgment that MSN has infringed at least one claim of each of the Asserted Patents by submitting or causing to be submitted its ANDA to obtain FDA approval for the commercial manufacture, use, import, offer for sale and/or sale in the U.S. of its generic version of HETLIOZ LQ[®] before the expiration of each of the Asserted Patents, enter judgment that the use of MSN's generic version of HETLIOZ LQ[®] in the U.S. before the expiration of each of the Asserted Patents will directly infringe at least one claim of each of the Asserted Patents, order that the effective date of any approval by the FDA of MSN's generic version of HETLIOZ LQ[®] be a date that is no earlier than the expiration of the last expiring Asserted Patent(s), or such later date as the Court may determine, enjoin MSN from the commercial manufacture, use, import, offer for sale and/or sale of its generic version of HETLIOZ LQ[®] until the expiration of each of the Asserted Patents or such later date as the Court may determine, and award monetary damages, to the extent applicable. The Company's lawsuit remains pending, and a trial that was scheduled to begin on September 14, 2026 has been rescheduled to begin on June 1, 2027.

Other Matters. From April 2022 to July 2024, the Company filed eighteen lawsuits in the DC District Court against the FDA to compel the FDA to produce records under the Freedom of Information Act (FOIA) regarding, among other matters: the FDA's denial of the Company's supplemental New Drug Application (sNDA) for HETLIOZ[®] in the treatment of jet lag disorder; cases in which the FDA waived its putative requirement of a 9-month non-rodent toxicity study before drugs can be tested on human patients for extended durations; communications external to and within the FDA relating to NEREUS[™], HETLIOZ[®] and Fanapt[®]; a warning letter that the FDA sent to the Company concerning its webpages for HETLIOZ[®] and Fanapt[®]; the FDA's removal of a clinical trials design presentation from its website; discipline reviews relating to the FDA's evaluations of the Company's sNDA for HETLIOZ[®] and a third-party sNDA for jet lag; internal standard operating procedures or guidance relating to the FDA's processing of incoming FOIA requests; and bioequivalence and other study reports submitted relating to the FDA's consideration of tasimelteon ANDAs. Nine of these lawsuits have since been resolved in the Company's favor and the other nine remain outstanding. The FDA has failed to respond and provide the requested documents within the statutory timeframe with respect to each of these nine outstanding cases. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations and declare that its lack of compliance violates FOIA.

In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ[®] in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing. The FDA published the notice of an opportunity for a hearing on October 11, 2022. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations and declare that its lack of compliance violates the FDCA and the FDA regulations. In January 2024, the DC District Court held an oral argument on dispositive cross-motions, following which the DC District Court granted in part the Company's motion for summary judgment. The DC District Court ruled that the FDA violated the statute and ordered the FDA to either finally resolve the Company's application or commence a hearing on or before March 5, 2024. In March 2024, the Company and the FDA filed a consent motion for entry of final judgment in the Company's favor on its APA claim for the FDA's unreasonable delay in resolving the hearing request, following which the FDA refused to hold a hearing or approve the Company's sNDA for HETLIOZ[®] in the treatment of jet lag disorder. The Company subsequently filed a petition for review in the DC Circuit. Under the FDCA, the FDA has an obligation to either approve an sNDA or to hold a hearing on the application's approvability. The Company's petition asks the DC Circuit to set aside the FDA's order refusing to hold a hearing and refusing approval. In January 2025, the DC Circuit held an oral argument. In August 2025, the DC Circuit issued a decision in favor of the Company against the FDA, setting aside the FDA's refusal to hold a hearing on the Company's sNDA for HETLIOZ[®] in the treatment of jet lag disorder and remanding the case back to the FDA. In October 2025, the Company announced that it had entered into a collaborative framework with the FDA for the resolution of certain of its disputes regarding HETLIOZ[®] and NEREUS[™] (the FDA Agreement), pursuant to which, the FDA agreed to conduct an expedited re-review of the sNDA and the Company sought a temporary abeyance in these proceedings. In January 2026, the FDA notified the Company that, following its re-review of the sNDA, it has determined that the sNDA cannot be approved in its current form. In January 2026, the Company requested that the FDA Commissioner resume hearing proceedings. In March 2026, the Office of the Commissioner granted the Company's hearing request. In July 2026, the presiding judge scheduled a hearing to begin on December 14, 2026.

In May 2023, the Company filed a lawsuit in the U.S. Court of Federal Claims (Federal Claims Court) against the federal government for the uncompensated taking and misuse of the Company's trade secrets and confidential information. The Company believes that the FDA violated the Fifth Amendment's due process clause by improperly providing confidential details from the Company's drug master files for HETLIOZ[®] and Fanapt[®] to generic drug manufacturers during the FDA's review of the manufacturers' ANDAs. The Company has asked the Federal Claims Court to, among other things, declare that the FDA's disclosure of the Company's confidential commercial information constitutes a taking for purposes of the Fifth

Amendment and award just compensation. The federal government filed a motion to dismiss the complaint, which the Company opposed. In January 2024, the Federal Claims Court held an oral argument on the motion to dismiss, following which the Federal Claims Court issued a decision denying in part the government's motion, allowing the Company's takings claim to proceed. In April 2024, the government filed a judgment on the pleadings, to which the Company opposed in July 2024 and the government replied in August 2024. In December 2024, the Federal Claims Court held an oral argument on the motion for judgment on the pleadings and in January 2025, the Federal Claims Court ruled against the Company. In February 2025, the Company appealed the ruling to the U.S. Court of Appeals for the Federal Circuit. The Company's appeal remains pending.

In February 2024, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with its statutory obligations under the FDCA and its implementing regulations, and to challenge the FDA's complete response letter and 60-day filing regulations, which the Company believes do not absolve the FDA of its statutory responsibilities. Under the FDCA, the FDA has an obligation to either approve the Company's sNDA for HETLIOZ® in the treatment of insomnia characterized by difficulties with sleep initiation within 180 days of the filing of the sNDA or give the Company a notice of an opportunity for a hearing. The Company submitted the sNDA on May 4, 2023. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations, declare that its lack of compliance violates the FDCA and the FDA regulations and declare the FDA's complete response letter and 60-day filing regulations unlawful. In June 2024, the Company filed a motion for summary judgment and the FDA published a notice of opportunity for a hearing. In July 2024, the FDA opposed the Company's motion for summary judgment. In September 2024, the DC District Court held an oral argument on the dispositive cross motions. In March and April 2025, the parties provided supplemental briefing. In May 2025, the DC District Court held a further hearing on the supplemental briefings. In September 2025, the Company filed a motion to stay proceedings in the case until January 2026 pursuant to the FDA Agreement. In January 2026, the Company and the FDA asked the DC District Court to lift the abeyance. In April 2026, the DC District Court consolidated this action with the Company's action challenging the FDA's compliance with its statutory obligations under the FDCA with respect to the Company's NDA for NEREUS™ to prevent vomiting induced by motion. The Company's lawsuit remains pending.

In August 2024, the Company filed a lawsuit against the FDA in the DC District Court challenging FDA decisionmakers' authority under the Appointments Clause of the U.S. Constitution to render a decision on the Company's new drug application for NEREUS™ to treat symptoms of gastroparesis. In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for NEREUS™ for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024. In September 2024, the DC District Court denied the motion. The Company filed a motion for summary judgment in December 2024, and in January 2025, the FDA opposed the motion and cross-moved to dismiss and for summary judgment. In February 2025, the Company filed its reply and opposition, to which the FDA replied in March 2025. In July 2026, the DC District Court held an oral argument, following which it denied the Company's summary judgment motion and granted the FDA's cross motion to dismiss.

In February 2025, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with its statutory obligations under the FDCA and its implementing regulations and to challenge the FDA's reliance on PDUFA deadlines and its complete response letter and 60-day filing regulations, which the Company believes do not absolve the FDA of its statutory responsibilities. Under the FDCA, the FDA has an obligation to either approve the Company's NDA for NEREUS™ to prevent vomiting induced by motion within 180 days of the filing of the NDA or give the Company a notice of an opportunity for a hearing. The Company submitted the NDA on December 30, 2024. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations, declare that its lack of compliance violates the FDCA and the FDA regulations and declare the FDA's complete response letter and 60-day filing regulations and adherence to PDUFA deadlines unlawful. Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUS™ in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025. In April 2025, the Company filed a motion for summary judgment regarding its motion sickness NDA and requested to file summary judgment regarding its gastroparesis NDA. In May 2025, the DC District Court held a hearing on the motion regarding the motion sickness NDA, and the FDA approved the motion sickness NDA in December 2025. The Center for Drug Evaluation and Research issued a proposed order denying a hearing on the gastroparesis NDA in July 2025. In September 2025, the Company filed a motion to stay proceedings in the DC District Court regarding the gastroparesis NDA until January 2026 pursuant to the FDA Agreement. In January 2026, the Company and the FDA asked the DC District Court to lift the abeyance. In April 2026, the DC District Court consolidated this action with the Company's action challenging the FDA's compliance with its statutory obligations under the FDCA with respect to the Company's HETLIOZ® sNDA in the treatment of insomnia characterized by difficulties with sleep initiation. The Company's lawsuit remains pending. The Company is currently assessing its options with respect to the litigation.

In April 2025, the Company filed a petition for review in the U.S. Court of Appeals for the DC Circuit seeking review of the FDA's final order refusing to hold a hearing or to approve the Company's sNDA for HETLIOZ® in the treatment of insomnia associated with difficulties with sleep initiation. Under the FDCA, the FDA has an obligation to either approve an sNDA or to

hold a hearing on the application's approvability. The Company's petition asks the DC Circuit to set aside the FDA's order refusing to hold a hearing and refusing approval. The Company's petition for review remains pending, and an oral argument is scheduled for September 23, 2026.

In March 2026, the Company filed a petition for review in the U.S. Court of Appeals for the DC Circuit seeking review of the FDA's final order refusing to hold a hearing or to approve the Company's NDA for NEREUSTM in gastroparesis. Under the FDCA, the FDA has an obligation to either approve an sNDA or to hold a hearing on the application's approvability. The Company's petition asks the DC Circuit to set aside the FDA's order refusing to hold a hearing and refusing approval. The Company's petition for review remains pending.

In April 2026, the Company filed a lawsuit in the DC District Court against the FDA challenging the FDA's partial clinical hold preventing the Company from studying the safety of NEREUSTM in gastroparesis patients through a 52-week open-label safety study. The FDA based its partial clinical hold on the Company's refusal to perform a repeat-dose toxicity study in a non-rodent species of at least 9 months and on the FDA's refusal to issue marketing approval for NEREUSTM to treat gastroparesis symptoms. However, under the FDA Modernization Act 2.0, nonclinical studies may include non-animal alternatives, and a decision regarding marketing approval does not determine whether to allow a clinical investigation. The Company has also challenged the FDA's decision regarding marketing approval. The Company believes that the FDA's basis for the partial clinical hold is contrary to law and exceeds the FDA's statutory authority. The Company has asked the DC District Court to, among other things, set aside the FDA's partial clinical hold and declare the FDA's partial clinical hold as unlawful. The Company's lawsuit remains pending.

ITEM 2 Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vanda Pharmaceuticals Inc. (we, our, us or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

We strive to advance novel approaches to bring important new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.

Our commercial portfolio is currently comprised of five products: Fanapt® (iloperidone) and BYSANTI™ (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS), PONVORY® (ponesimod) for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease and NEREUS™ (tradipitant) for the prevention of vomiting induced by motion (collectively, our commercial products). In addition, we have a number of drugs and/or additional indications for current products in development, including:

- Fanapt® long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension;
- BYSANTI™ for major depressive disorder (MDD);
- HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
- PONVORY® for the treatment of ulcerative colitis and psoriasis;
- Quimilza™ (imsidolimab), an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
- NEREUS™ for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
- VQW-765, a small molecule alpha-7 nicotinic acetylcholine receptor partial agonist, for the treatment of social/performance anxiety and psychiatric disorders;
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and VPO-227 for the treatment of secretory diarrhea disorders, including cholera;
- VTR-297, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of hematologic malignancies and onychomycosis and with potential use as a treatment for several oncology indications; and
- Antisense oligonucleotide (ASO) molecules, including VGA-157A for Parkinson's disease, VCA-894A for the treatment of Charcot-Marie-Tooth Disease, Type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene and VGT-1849A for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy.

Operational Highlights

Key Commercial Highlights

- Fanapt® saw continued strong momentum in Q2 2026, with total prescriptions (TRx) up 31% and new-to-brand prescriptions (NBRx) up 32% versus Q2 2025. Since commercial expansion following the approval of bipolar disorder, Fanapt® has seen significant growth, with TRx up 62% and NBRx up 300% versus Q2 2024.
- BYSANTI™ received FDA approval for the treatment of bipolar I disorder and schizophrenia in Q1 2026 and is expected to launch in the second half of 2026. BYSANTI™ is protected by data exclusivity through February 20, 2031 and multiple patents, the latest of which expires on May 31, 2044.
- In May 2026, the early commercial launch of NEREUS™ was initiated with a direct-to-consumer offering via the web portal nereus.us. Personal promotion is expected to commence later in 2026.

Key Regulatory & Clinical Development Highlights

Upcoming Clinical Milestones

- Our ongoing late-stage clinical studies are progressing rapidly and are expected to generate topline results in 2026 or early 2027, including:
 - The Thetis Phase III study of NEREUSTM for the prevention of vomiting in patients receiving GLP-1 receptor agonist therapies, with results expected in 2026.
 - The Phase III study of VQW-765 in the treatment of adults with social anxiety disorder, with results expected in 2026.
 - The Phase III study of HETLIOZ[®] in the treatment of delayed sleep phase disorder (DSPD) with results expected in 2026.
 - The Phase III study of BYSANTITM as a once-daily adjunctive treatment for major depressive disorder (MDD), with results expected in the first half of 2027.

Other Updates

- The Biologics License Application (BLA) for QuimilzaTM in GPP is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026. The results of the pivotal clinical study were published in the April 28, 2026 issue of the New England Journal of Medicine (NEJM) Evidence.
- In May 2026, Vanda announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to QuimilzaTM for the treatment of GPP. In July 2026, we announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) had adopted a positive opinion recommending orphan drug designation for QuimilzaTM for the treatment of GPP.
- In July 2026, we announced that the FDA had granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder.
- We continue to progress the FDA formal hearing regarding HETLIOZ[®] for the treatment of jet lag disorder. The proceeding, a rare administrative hearing process granted after the D.C. Circuit set aside the FDA's prior refusal to approve the application, is advancing according to schedule and is expected to culminate in a five-day hearing before the Administrative Law Judge in December 2026.

Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our ability, alone or with others, to complete the development of, obtain regulatory approvals for and manufacture, market and sell our products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry and other risks that are detailed in Part I, Item 1A, *Risk Factors*, of our annual report on Form 10-K (Annual Report) for the year ended December 31, 2025 and Item 1A, *Risk Factors*, of any Quarterly Report filed subsequent to our Annual Report.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies, including estimates, assumptions and judgments, from those described in Part II, Item 7, *Management's Discussion and Analysis of Financial Condition and Results of Operations*, included in the Annual Report. A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements included in the Annual Report. However, we believe that the following accounting policies are important to understanding and evaluating our reported financial results as they involve the most significant judgments and estimates used in the preparation of our condensed consolidated financial statements, and we have accordingly included them in this discussion.

Revenue from net product sales. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We recognize revenue when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Sales taxes, value-added taxes and usage-based taxes are excluded from revenues.

Fanapt® and NEREUS™ are available in the U.S. for distribution through a limited number of wholesalers and are also available in retail pharmacies. In addition, NEREUS™ is available by prescription directly through the nereus.us website. HETLIOZ® is available in the U.S. for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORY® is available in the U.S. for distribution primarily through a limited number of specialty distributors and specialty pharmacies. We invoice and record revenue when our customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., we have a distribution agreement for the commercialization of Fanapt® in Israel and sell HETLIOZ® in Germany. Receivables are carried at transaction price paid by the wholesalers, specialty pharmacies and specialty distributors, net of estimated prompt-pay discounts and allowance for credit losses. Payment terms differ by customer, but are based on customary commercial terms and typically range between thirty and sixty days. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.

The transaction price is determined based upon the consideration to which we will be entitled in exchange for transferring product to the customer. Our product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. Where appropriate, our estimates of variable consideration included in the transaction price consider a range of possible outcomes. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, if any, which are estimated using historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits. Variable consideration may be constrained and is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. If actual results in the future vary from our estimates, we adjust our estimate in the period identified, which would affect net product sales in the period such variances become known. During the six months ended June 30, 2026, we constrained NEREUS™ net product sales. The constrained revenue relates to the uncertainties of patient demand and product returns related to the elevated levels of inventory on hand at wholesalers.

Net product sales of NEREUS™ made directly to patients through the nereus.us website are cash-pay transactions that are not subject to commercial or government payor insurance benefits and, accordingly, are not subject to the rebate, chargeback, Medicare Part D and co-pay assistance allowances described above.

Reserves for variable consideration are classified as product revenue allowances on the Condensed Consolidated Balance Sheets, with the exception of prompt-pay discounts, which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Condensed Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, Medicare inflationary rebates, which are billed on an annual basis beginning in 2025, and product returns that are resolved during the product expiry period specified in the customer contract. Furthermore, inventory stocking of HETLIOZ® at specialty pharmacy customers since the entrance of generic competition in early 2023 has resulted in longer periods to resolve these uncertainties related to variable consideration. We currently record sales allowances for the following:

- *Prompt-pay:* Wholesalers, specialty pharmacies and specialty distributors, our direct customers, are generally offered discounts for prompt payment. We expect that these direct customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.
- *Rebates:* Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors, including the Medicare Part D inflationary rebate. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid and Medicare. The allowances for rebates are based on statutory or contracted discount rates and estimated patient utilization.
- *Chargebacks:* Chargebacks are discounts that occur when contracted indirect customers purchase directly from wholesalers, specialty pharmacies and specialty distributors. Contracted indirect customers, which currently consist

primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The wholesaler, specialty pharmacy or specialty distributor, in turn, charges back the difference between the price initially paid by the wholesaler, specialty pharmacy or specialty distributor and the discounted price paid to the wholesaler, specialty pharmacy or specialty distributor by the contracted customer.

- **Medicare Part D rebates:** Prior to January 1, 2025, the Medicare Part D prescription drug benefit required manufacturers to fund approximately 70% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. We accounted for the Medicare Part D coverage gap using a point of sale model. Beginning January 1, 2025, the Medicare Part D coverage gap discount program was replaced with a new discounting program under the Inflation Reduction Act of 2022. The Medicare Part D benefit redesign has resulted in overall higher discounts for our Medicare payor segment relative to the previous Medicare Part D prescription drug coverage gap discount program. Under the redesigned Medicare Part D program, applicable drugs dispensed to applicable beneficiaries are subject to manufacturer discounts of 10% during the initial coverage phase and 20% during the catastrophic coverage phase. Under the Medicare Part D benefit redesign, we are a specified manufacturer whose applicable drugs for applicable beneficiaries who are Low Income Subsidy eligible under section 1860D-14(a) of the Social Security Act are subject to lower applicable discounts during the phase-in period. Estimates for expected Medicare Part D rebates are based, in part, on historical activity and, where available, actual and pending prescriptions when we have validated the insurance benefits.
- **Service fees:** We receive sales order management, data and distribution services from certain customers, for which we are assessed fees. These fees are based on contracted terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.
- **Co-pay assistance:** Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. Co-pay assistance utilization is based on information provided by our third-party administrator.
- **Product returns:** We generally offer direct customers a limited right to return, as contractually defined with our customers. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has passed, prescription trends and other relevant factors. We do not expect returned products to be resalable. There was no right of return asset as of June 30, 2026 or December 31, 2025.

The following table summarizes sales discounts and allowance activity as of and for the six months ended June 30, 2026:

<i>(in thousands)</i>	Rebates & Chargebacks	Discounts, Returns and Other	Total
Balances at December 31, 2025	\$ 63,356	\$ 14,709	\$ 78,065
Provision related to current period sales	64,116	36,072	100,188
Adjustments for prior period sales	(2,880)	(39)	(2,919)
Credits/payments made	(58,228)	(21,764)	(79,992)
Balances at June 30, 2026	<u>\$ 66,364</u>	<u>\$ 28,978</u>	<u>\$ 95,342</u>

The provision of \$64.1 million for rebates and chargebacks for the six months ended June 30, 2026 and its ending balance at June 30, 2026 primarily represent Medicaid rebates. The provision of \$36.1 million for discounts, returns and other for the six months ended June 30, 2026 and its ending balance at June 30, 2026 primarily represents service fees, estimated product returns, co-pay assistance costs and prompt-pay discounts. NEREUS™ became commercially available in the U.S. in May 2026. The increase in the balance of discounts, returns and other as of June 30, 2026 relative to December 31, 2025 was primarily due to provisions for constrained revenue for the initial stocking of NEREUS™ by wholesalers.

Stock-based compensation. Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. We use the Black-Scholes-Merton option pricing model to determine the fair value of stock options. We use the Monte Carlo model to determine the fair value of performance restricted share units (PSUs). The determination of the fair value of stock options and PSUs on the date of grant using a valuation model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the expected term (stock options) or remaining performance period (PSUs) of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are

based on the historical volatility of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. As stock-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Research and development expenses. Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services for clinical trial use, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs and salaries, other employee-related costs and stock-based compensation for research and development personnel. We generally expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use.

Clinical trials are inherently complex, often involve multiple service providers and can include payments made to investigator physicians at study sites. Because billing for services often lags delivery of service by a substantial amount of time, we are often required to estimate a significant portion of our accrued clinical expenses. Our assessments include, but are not limited to: (i) an evaluation by the project manager of the work that has been completed during the period, (ii) measurement of progress prepared internally and/or provided by the third-party service provider, (iii) analyses of data that justify the progress, and (iv) management's judgment. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high.

Intangible assets and impairment of long-lived assets. Our intangible assets consist of capitalized license costs for products approved by the FDA or costs to acquire already commercialized products. We amortize our intangible assets on a straight-line basis over the estimated useful economic life of the related product patents. We assess the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include significant underperformance relative to expected, historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life, including our ability to defend and enforce patent claims and other intellectual property rights, and significant negative industry or economic trends. When we determine that the carrying value of our intangible assets may not be recoverable based upon the existence of one or more of the indicators of impairment, we measure any impairment based on the amount that carrying value exceeds fair value.

Income taxes. We assess the need for a valuation allowance against our deferred tax assets each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis is highly dependent upon historical and projected pretax income. Projected pretax income includes significant assumptions related to revenue, which could be affected by the success of the commercial launches of Fanapt® in bipolar I disorder, PONVORY® in RMS, NEREUS™ in the prevention of vomiting induced by motion, which became commercially available in the U.S. in May 2026, and BYSANTI™ for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia, which was approved in February 2026, and HETLIOZ® generic competition, as well as commercial and research and development activities, including spend on our commercial launches and late-stage clinical activities and our ability to obtain regulatory approval from the FDA for products or new indications in development, among other factors. After considering all available positive and negative evidence, including but not limited to historical, current and future projected results and significant risks and uncertainties related to forecasts, we have concluded that it is not more likely than not that substantially all of our deferred tax assets are realizable in future periods and maintained a valuation allowance against all net deferred tax assets as of June 30, 2026 and December 31, 2025. The valuation allowance was recorded in the fourth quarter of 2025, resulting in a non-cash income tax expense of \$113.7 million for the year ended December 31, 2025. If we have cumulative pretax income in future periods and if our projections indicate pretax income in future periods or if there are meaningful changes to our business operations, the conclusion about the appropriateness of the valuation allowance could change in a future period. A future reduction of the valuation allowance, in whole or in part, would result in a non-cash income tax benefit during the period of reduction. The potential timing and amount of any future valuation allowance release has yet to

be determined and requires an analysis that is highly dependent upon historical and future projected earnings, among other factors. Any such adjustment could have a material impact on our financial position and results of operations.

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.

Recent Accounting Pronouncements

See Note 2, *Summary of Significant Accounting Policies*, to the condensed consolidated financial statements included in Part I of this Quarterly Report for information on recent accounting pronouncements.

Results of Operations

We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners' ability to continue to successfully commercialize our products, including our newest products, NEREUSTM for the prevention of vomiting induced by motion, which was approved in December 2025 and became commercially available in the U.S. in May 2026, and BYSANTITM for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia, which was approved in February 2026, the impact of regulatory changes to the pharmaceutical industry such as the Medicare Part D provisions of the Inflation Reduction Act of 2022, any possible payments made or received pursuant to license agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals and the status of existing and future potential litigation involving our products and intellectual property. See Note 14, *Legal Matters*, to the condensed consolidated financial statements included in Part I of this Quarterly Report for information on material legal matters.

Three months ended June 30, 2026 compared to three months ended June 30, 2025

Revenues. Total revenues decreased by \$2.1 million, or 4%, to \$50.5 million for the three months ended June 30, 2026 compared to \$52.6 million for the three months ended June 30, 2025. Revenue from net product sales was as follows:

(in thousands)	Three Months Ended			
	June 30, 2026	June 30, 2025	Net Change	Percent
Fanapt [®] net product sales	\$ 35,989	\$ 29,294	\$ 6,695	23 %
HETLIOZ [®] net product sales	5,576	16,192	(10,616)	(66)%
PONVORY [®] net product sales	7,935	7,104	831	12 %
NEREUS TM net product sales	1,029	—	1,029	N/A
Total net product sales	<u>\$ 50,529</u>	<u>\$ 52,590</u>	<u>\$ (2,061)</u>	<u>(4)%</u>

Fanapt[®] net product sales increased by \$6.7 million, or 23%, to \$36.0 million for the three months ended June 30, 2026 compared to \$29.3 million for the three months ended June 30, 2025. The increase to net product sales was primarily attributable to an increase in volume. An amount of variable consideration related to Fanapt[®] net product sales is subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2025.

HETLIOZ[®] net product sales decreased by \$10.6 million, or 66%, to \$5.6 million for the three months ended June 30, 2026 compared to \$16.2 million for the three months ended June 30, 2025. The decrease to net product sales was attributable to a decrease in volume. Since the entrance of generic competition in the first quarter of 2023, HETLIOZ[®] dispenses have decreased. Additionally, inventory levels at our specialty pharmacy customers have been elevated relative to inventory levels prior to the entrance of generic competition. The elevated levels of inventory have resulted in longer periods to resolve uncertainties related to variable consideration. HETLIOZ[®] net product sales have been and may continue to fluctuate from quarter to quarter depending on when specialty pharmacy customers purchase again. During the second quarter of 2026, there was destocking of inventory by certain of our specialty pharmacy customers, as well as orders, totaling approximately \$7.0 million in revenue, that were shipped on June 29, 2026 and arrived on July 1, 2026, both resulting in a decline in volume. These orders that did not arrive by quarter end will be recognized as revenue in the third quarter of 2026. HETLIOZ[®] net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.

PONVORY[®] net product sales increased by \$0.8 million, or 12%, to \$7.9 million for the three months ended June 30, 2026 compared to \$7.1 million for the three months ended June 30, 2025. An amount of variable consideration related to

PONVORY® net product sales is subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2024.

NEREUS™ became commercially available in the U.S. in May 2026. NEREUS™ net product sales were \$1.0 million for the three months ended June 30, 2026. During the three months ended June 30, 2026, there was an initial stocking of NEREUS™ by wholesalers and we constrained NEREUS™ net product sales. The constrained revenue relates to the uncertainties of patient demand and product returns related to the elevated levels of inventory on hand at wholesalers.

Cost of goods sold. Cost of goods sold increased by \$0.8 million, or 30%, to \$3.6 million for the three months ended June 30, 2026 compared to \$2.7 million for the three months ended June 30, 2025. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs.

Third-party royalty costs were 6% of Fanapt® net product sales and 5% of HETLIOZ® net product sales in Germany. Third-party royalty costs on HETLIOZ® net product sales in Germany will end in October 2026 and third-party royalty costs on Fanapt® net product sales in the U.S. will end in November 2026. There are no third-party royalty costs on net sales of PONVORY®. Third-party royalty costs on NEREUS™ net product sales in the U.S. are tiered, up to the low double digits, and began with the U.S. commercial launch of NEREUS™ in May 2026.

We evaluate the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life and build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage and generic competition. Our inventory balance consisted of \$7.1 million of HETLIOZ® product and \$3.1 million of other products as of June 30, 2026. Our inventory balance consisted of \$7.8 million of HETLIOZ® product and \$3.2 million of other products as of December 31, 2025. Net product sales during the three months ended June 30, 2026 was derived from zero-cost inventory related to inventory manufactured prior to when FDA approval of NEREUS™ was determined to be probable, which was previously expensed as research and development expense. For the three months ended June 30, 2026, the increase to cost of goods sold would not have been material if we included zero-cost inventory. As of June 30, 2026, the remaining zero-cost inventory that was previously expensed was \$5.0 million, which consisted of work-in-process.

Research and development expenses. Research and development expenses increased by \$15.0 million, or 68%, to \$37.0 million for the three months ended June 30, 2026 compared to \$22.0 million for the three months ended June 30, 2025. The increase was primarily due to higher expenses on our VQW-765 and various of our other development programs.

The following table summarizes the costs of our product development initiatives for the three months ended June 30, 2026 and 2025:

(in thousands)	Three Months Ended	
	June 30, 2026	June 30, 2025
Direct project costs (1)		
Fanapt®	\$ 5,900	\$ 3,485
BYSANTI™	5,068	3,709
HETLIOZ®	5,288	3,774
PONVORY®	2,436	1,548
NEREUS™	6,994	3,918
VQW-765	4,888	413
CFTR	882	1,932
VTR-297	1,321	808
Other	2,161	386
Total direct project costs	34,938	19,973
Indirect project costs (1)		
Stock-based compensation	583	596
Other indirect overhead	1,432	1,421
Total indirect project costs	2,015	2,017
Total research and development expense	\$ 36,953	\$ 21,990

- (1) We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.

We expect to incur significant research and development expenses as we continue to develop our products and continue our efforts to expand our product pipeline.

Selling, general and administrative expenses. Selling, general and administrative expenses increased by \$7.2 million, or 11%, to \$71.8 million for the three months ended June 30, 2026 compared to \$64.6 million for the three months ended June 30, 2025. The increase in selling, general and administrative expenses was primarily the result of an increase in spending on our continued commercialization efforts for our products, including the U.S. commercial launch of NEREUSTM initiated in May 2026 and the expansion of our sales force during 2025.

Intangible asset amortization. Intangible asset amortization was \$2.0 million for the three months ended June 30, 2026 compared to \$1.8 million for the three months ended June 30, 2025. Intangible asset amortization increased in 2026 due to the amortization of the NEREUSTM intangible asset, which was capitalized in December 2025.

Other income, net. Other income, net was \$1.4 million for the three months ended June 30, 2026 compared to \$3.6 million for the three months ended June 30, 2025. Other income primarily consists of investment income on our marketable securities.

Provision (benefit) for income taxes. We recorded an income tax provision of \$0.1 million and a benefit for income taxes of \$7.7 million for the three months ended June 30, 2026 and 2025, respectively. The income tax provision for the three months ended June 30, 2026 was driven by discrete income tax expense of \$0.1 million. The income tax benefit for the three months ended June 30, 2025 was primarily driven by the estimated effective tax rate for the year as well as discrete income tax expense of \$0.4 million.

Six months ended June 30, 2026 compared to six months ended June 30, 2025

Revenues. Total revenues decreased by \$0.4 million to \$102.2 million for the six months ended June 30, 2026 compared to \$102.6 million for the six months ended June 30, 2025. Revenues were as follows:

(in thousands)	Six Months Ended			
	June 30, 2026	June 30, 2025	Net Change	Percent
Fanapt [®] net product sales	\$ 65,549	\$ 52,839	\$ 12,710	24 %
HETLIOZ [®] net product sales	21,523	37,064	(15,541)	(42)%
PONVORY [®] net product sales	14,146	12,728	1,418	11 %
NEREUS TM net product sales	1,029	—	1,029	N/A
Total net product sales	\$ 102,247	\$ 102,631	\$ (384)	— %

Fanapt[®] net product sales increased by \$12.7 million, or 24%, to \$65.5 million for the six months ended June 30, 2026 compared to \$52.8 million for the six months ended June 30, 2025. The increase to net product sales was primarily attributable to an increase in volume, partially offset by a decrease in price net of deductions. An amount of variable consideration related to Fanapt[®] net product sales is subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2025.

HETLIOZ[®] net product sales decreased by \$15.5 million, or 42%, to \$21.5 million for the six months ended June 30, 2026 compared to \$37.1 million for the six months ended June 30, 2025. The decrease to net product sales was attributable to a decrease in volume. Since the entrance of generic competition in the first quarter of 2023, HETLIOZ[®] dispenses have decreased. Additionally, inventory levels at our specialty pharmacy customers have been elevated relative to inventory levels prior to the entrance of generic competition. The elevated levels of inventory have resulted in longer periods to resolve uncertainties related to variable consideration. HETLIOZ[®] net product sales have been and may continue to fluctuate from quarter to quarter depending on when specialty pharmacy customers purchase again. During the second quarter of 2026, there was destocking of inventory by certain of our specialty pharmacy customers, as well as orders, totaling approximately \$7.0 million in revenue, that were shipped on June 29, 2026 and arrived on July 1, 2026, both resulting in a decline in volume. These orders that did not arrive by quarter end will be recognized as revenue in the third quarter of 2026. HETLIOZ[®] net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.

PONVORY[®] net product sales increased by \$1.4 million, or 11%, to \$14.1 million for the six months ended June 30, 2026 compared to \$12.7 million for the six months ended June 30, 2025. An amount of variable consideration related to PONVORY[®] net product sales is subject to dispute, of which approximately \$3.0 million was recognized for the three months ended December 31, 2024.

NEREUS[™] became commercially available in the U.S. in May 2026. NEREUS[™] net product sales were \$1.0 million for the six months ended June 30, 2026. During the six months ended June 30, 2026, there was an initial stocking of NEREUS[™] by wholesalers and we constrained NEREUS[™] net product sales. The constrained revenue relates to the uncertainties of patient demand and product returns related to the elevated levels of inventory on hand at wholesalers.

Cost of goods sold. Cost of goods sold increased by \$0.5 million, or 7%, to \$6.7 million for the six months ended June 30, 2026 compared to \$6.3 million for the six months ended June 30, 2025. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs.

Third-party royalty costs were 6% of Fanapt[®] net product sales and 5% of HETLIOZ[®] net product sales in Germany. Third-party royalty costs on HETLIOZ[®] net product sales in Germany will end in October 2026 and third-party royalty costs on Fanapt[®] net product sales in the U.S. will end in November 2026. There are no third-party royalty costs on net sales of PONVORY[®]. Third-party royalty costs on NEREUS[™] net product sales in the U.S. are tiered up to the low double digits, and began with the U.S. commercial launch of NEREUS[™] in May 2026.

We evaluate the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life and build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage, and generic competition. Our inventory balance consisted of \$7.1 million of HETLIOZ[®] product and \$3.1 million of other products as of June 30, 2026. Our inventory balance consisted of \$7.8 million of HETLIOZ[®] product and \$3.2 million of other products as of December 31, 2025. Net product sales during the six months ended June 30, 2026 was derived from zero-cost inventory related to inventory manufactured prior to when FDA approval of NEREUS[™] was determined to be probable, which was previously expensed as research and development expense. For the six months ended June 30, 2026, the increase to cost of goods sold would not have been material if we included zero-cost inventory. As of June 30, 2026, the remaining zero-cost inventory that was previously expensed was \$5.0 million, which consisted of work-in-process.

Research and development expenses. Research and development expenses increased by \$7.7 million, or 13%, to \$65.4 million for the six months ended June 30, 2026 compared to \$57.7 million for the six months ended June 30, 2025. The increase was primarily due to an increase in expenses for our VQW-765, Fanapt[®] and various of our other development programs, partially offset by lower expenses on our Quimilza[™] program. Research and development expenses for the six months ended June 30, 2025 included an upfront payment to AnaptysBio, Inc. for the exclusive, global license to develop, manufacture, and commercialize Quimilza[™] and drug supply.

The following table summarizes the costs of our product development initiatives for the six months ended June 30, 2026 and 2025:

(in thousands)	Six Months Ended	
	June 30, 2026	June 30, 2025
Direct project costs (1)		
Fanapt®	\$ 10,859	\$ 7,235
BYSANTI™	9,318	6,399
HETLIOZ®	8,061	6,914
PONVORY®	5,285	3,890
NEREUS™	9,805	8,015
Quimilza™	2,974	14,370
VQW-765	8,209	650
CFTR	2,866	3,387
VTR-297	2,763	1,583
Other	1,231	850
Total direct project costs	61,371	53,293
Indirect project costs (1)		
Stock-based compensation	1,184	1,361
Other indirect overhead	2,833	3,048
Total indirect project costs	4,017	4,409
Total research and development expense	\$ 65,388	\$ 57,702

- (1) We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.

We expect to incur significant research and development expenses as we continue to develop our products and continue our efforts to expand our product pipeline.

Selling, general and administrative expenses. Selling, general and administrative expenses increased by \$25.5 million, or 22%, to \$140.2 million for the six months ended June 30, 2026 compared to \$114.7 million for the six months ended June 30, 2025. The increase in selling, general and administrative expenses was primarily the result of an increase in spending on our continued commercialization efforts for our commercial launches of our products, including the U.S. commercial launch of NEREUS™ initiated in May 2026 and the expansion of our sales force during 2025.

Intangible asset amortization. Intangible asset amortization was \$4.0 million and \$3.5 million for the six months ended June 30, 2026 and 2025, respectively. Intangible asset amortization increased in 2026 due to the amortization of the NEREUS™ intangible asset, which was capitalized in December 2025.

Other income, net. Other income, net was \$3.2 million for the six months ended June 30, 2026 compared to \$7.3 million for the six months ended June 30, 2025. Other income primarily consists of investment income on our marketable securities.

Provision (benefit) for income taxes. We recorded an income tax provision of \$0.3 million and a benefit for income taxes of \$15.6 million for the six months ended June 30, 2026 and 2025, respectively. The income tax provision for the six months ended June 30, 2026 was driven by discrete income tax expense of \$0.2 million. The income tax benefit for the six months ended June 30, 2025 was primarily driven by the estimated effective tax rate for the year as well as discrete income tax expense of \$0.8 million.

Liquidity and Capital Resources

As of June 30, 2026, our total cash and cash equivalents and marketable securities were \$170.0 million compared to \$263.8 million at December 31, 2025. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with

commercial banks and financial institutions and commercial paper of high-quality corporate issuers. Our marketable securities consist of investments in government-sponsored and corporate enterprises and commercial paper.

Our liquidity resources as of June 30, 2026 and December 31, 2025 are summarized as follows:

(in thousands)	June 30, 2026	December 31, 2025
Cash and cash equivalents	\$ 55,882	\$ 84,851
Marketable securities:		
U.S. Treasury and government agencies	97,804	153,735
Corporate debt	16,343	25,261
Total marketable securities	114,147	178,996
Total cash, cash equivalents and marketable securities	\$ 170,029	\$ 263,847

As of June 30, 2026, we maintained all of our cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.

In the normal course of our business, we regularly enter into agreements with third-party vendors under fee service arrangements which generally may be terminated on 90 days' notice without incurring additional charges, other than charges for work completed or materials procured but not paid for through the effective date of termination and other costs incurred by our contractors in closing out work in progress as of the effective date of termination. Occasionally, we enter into short- and long-term agreements with third-party vendors that are non-cancellable. Our short-term non-cancellable purchase commitments primarily relate to inventory and clinical manufacturing purchase commitments, for which the production is expected to be completed within a one-year period, and certain marketing activities. Our non-cancellable purchase commitments for agreements with a remaining non-cancellable term longer than one year from June 30, 2026 primarily relate to commitments for marketing activities, inventory purchase commitments for certain of our commercial products and data services. Various other long-term agreements entered into for services with other third-party vendors are cancellable in nature or contain variable commitment terms within the agreement that are within our control. We also have long-term contractual obligations related to our leases and license agreements. See Note 8, *Commitments and Contingencies*, to the condensed consolidated financial statements included in Part I of this Quarterly Report for more information about these commitments.

Other than as disclosed in Note 8, *Commitments and Contingencies*, to the condensed consolidated financial statements included in Part I of this Quarterly Report, there have been no material changes to our long-term contractual obligations as disclosed in Part II, Item 7, *Management's Discussion and Analysis of Financial Condition and Results of Operations*, of our Annual Report. For further information regarding our long-term non-cancellable purchase commitments, leases and license agreements, see Note 8, *Commitments and Contingencies*.

We do not have any off-balance sheet arrangements.

Based on our current operating plans, which include continued investment in support of our commercial products, including the ongoing commercial launch of NEREUSTM for the prevention of vomiting induced by motion, which became commercially available in the U.S. in May 2026, and the upcoming commercial launch of BYSANTITM for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia, continued clinical development of our commercial and other products, pursuit of regulatory approval of QuimilzaTM, pursuit of further regulatory approvals for our currently approved products and payments due upon achievement of milestones under our license agreements, we believe that our cash, cash equivalents and marketable securities and cash received from product sales will be sufficient for at least the next 12 months as of the date the financial statements were issued. Our activities will necessitate significant working capital through 2026 and beyond, and future cash requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue, the scope and costs of our commercial, manufacturing and process development activities, including the commercial launches of NEREUSTM and BYSANTITM, a regulatory approval of QuimilzaTM, the magnitude of our discovery, preclinical and clinical development programs and potential costs to acquire or license the rights to additional products.

We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible into common stock. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings may also

significantly dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities, which could harm our business, financial condition and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.

Cash Flow

The following table summarizes our net cash flows from operating, investing and financing activities for the six months ended June 30, 2026 and 2025:

(in thousands)	Six Months Ended		
	June 30, 2026	June 30, 2025	Net Change
Net cash provided by (used in):			
Operating activities:			
Net loss	\$ (111,080)	\$ (56,701)	\$ (54,379)
Non-cash charges	12,496	(5,106)	17,602
Net change in operating assets and liabilities	17,296	13,408	3,888
Operating activities	(81,288)	(48,399)	(32,889)
Investing activities:			
Acquisition of intangible asset	(10,000)	—	(10,000)
Purchases of property and equipment	(411)	(735)	324
Net purchases, sales and maturities of marketable securities	64,455	29,367	35,088
Investing activities	54,044	28,632	25,412
Financing activities:			
Principal payments on finance leases	(1,632)	(834)	(798)
Tax obligations paid in connection with settlement of restricted stock units	—	(915)	915
Financing activities	(1,632)	(1,749)	117
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(93)	183	(276)
Net change in cash, cash equivalents and restricted cash	<u>\$ (28,969)</u>	<u>\$ (21,333)</u>	<u>\$ (7,636)</u>

Operating Activities. Cash flows used in operating activities during the six months ended June 30, 2026 were \$81.3 million, an increase of \$32.9 million compared to \$48.4 million during the six months ended June 30, 2025. The increase reflects an increase in net loss of \$54.4 million, \$3.9 million from the net change in operating assets and liabilities and \$17.6 million in non-cash charges primarily due to a valuation allowance against all of our deferred tax assets in 2026. The increase from net change in operating assets and liabilities was due to timing for our accounts receivable including NEREUSTM inventory stocking by wholesaler customers and HETLIOZ[®] destocking by certain specialty pharmacy customers during the second quarter of 2026, and product revenue allowances, including the impact of constraining NEREUSTM revenue in the second quarter of 2026.

Investing Activities. Cash flows provided by investing activities during the six months ended June 30, 2026 were \$54.0 million, an increase of \$25.4 million compared to \$28.6 million during the six months ended June 30, 2025. The change in investing activities primarily reflects the net use of cash and cash equivalents and maturities of the investments in our portfolio of marketable securities. The \$10.0 million milestone payment owed to Eli Lilly and Company for the FDA's approval of NEREUSTM for the prevention of vomiting induced by motion was accrued as of December 31, 2025 and paid in 2026.

Financing Activities. Cash flows used in financing activities during the six months ended June 30, 2026 were \$1.6 million, a decrease of \$0.1 million compared to \$1.7 million during the six months ended June 30, 2025. Financing activities include principal payments for our finance lease liabilities and tax obligations paid in connection with settlement of restricted stock units.

ITEM 3 Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes.

We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities that are generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of commercial paper, corporate notes and U.S. government agency notes and have maturities of less than two years. We do not believe that an increase in market rates would have any significant impact on the realized value of our cash equivalents and marketable securities.

We are also exposed to risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent that we enter into transactions denominated in currencies other than our subsidiaries' respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our condensed consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had, nor do we believe that a decrease or increase in any foreign currency exchange rates would have, a material impact on our results of operations.

ITEM 4 Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of June 30, 2026. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of June 30, 2026, the end of the period covered by this quarterly report on Form 10-Q, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the second quarter of 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1 Legal Proceedings

Information with respect to this item may be found in Note 14, *Legal Matters*, to the condensed consolidated financial statements in Part I of this quarterly report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A Risk Factors

We previously disclosed in Part I, Item 1A of our annual report on Form 10-K (Annual Report) for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026, important factors which could affect our business, financial condition, results of operations and future operations under the heading Risk Factors. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results

and the price of our common stock. Other than as set forth below, there have been no material changes to the risk factors disclosed in our Annual Report for the fiscal year ended December 31, 2025.

Our business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.

Existing free trade laws and regulations, such as the United States-Mexico-Canada Agreement, provide certain beneficial duties and tariffs for qualifying imports and exports, subject to compliance with the applicable classification and other requirements. Changes in laws or policies governing the terms of trade, and in particular increased trade restrictions, tariffs or taxes on imports from countries where we or our third-party suppliers manufacture or source products, could have a material adverse effect on our business and financial results. Recently there have been significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. On April 2, 2026, the President issued a proclamation under Section 232 of the Trade Expansion Act of 1962, following the completion of the U.S. Department of Commerce’s Section 232 investigation into the national security implications of pharmaceutical and active pharmaceutical ingredients (API) imports, imposing a 100% ad valorem tariff on imports of patented pharmaceutical products and associated pharmaceutical ingredients, including APIs. For the large pharmaceutical companies identified in the proclamation, the tariffs become effective on July 31, 2026; for all other importers, the tariffs become effective on September 29, 2026. The proclamation provides for reduced or zero tariff rates in certain circumstances, including exemptions for generic pharmaceuticals, U.S.-origin products, and certain specialty products, such as drugs for which all approved indications carry orphan drug designation under the Orphan Drug Act, subject to specified conditions. We do not have in-house manufacturing capability and depend on a limited number of third-party manufacturers and API formulators, certain of which are located outside the U.S. or source APIs, raw materials, laboratory equipment and research material and components from other countries. To the extent the new tariffs apply to our products or their inputs and are not subject to an exemption or reduced rate, they could increase our costs and reduce our margins. The extent and duration of these and any future tariffs and trade restrictions, and the resulting impact on general economic conditions and our business, are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, the availability and scope of exemptions or exclusions that may be granted, including any orphan drug exemption potentially relevant to certain of our products, the outcome of any legal challenges to these measures and the availability and cost of alternative sources of supply and availability and cost of alternative locations of manufacturing facility in the U.S. or lower tariff jurisdiction. Introducing a replacement manufacturer or supplier for our products requires a lengthy regulatory and commercial process, including FDA approval of chemistry, manufacturing and controls (CMC) changes, and there can be no guarantee that we could obtain necessary regulatory approvals in a timely fashion, or at all. As a result of these dynamics, we cannot predict the impact to our business of any future changes to the U.S.’s or other countries’ trading relationships or the impact of new laws or regulations adopted by the U.S. or other countries.

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3 Defaults Upon Senior Securities

None.

ITEM 4 Mine Safety Disclosures

Not applicable.

ITEM 5 Other Information

During the fiscal quarter ended June 30, 2026, none of our directors or officers informed us of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408. Furthermore, during the fiscal quarter ended June 30, 2026, we did not adopt or terminate a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.

ITEM 6 Exhibits

Exhibit Number	Description
3.1	<u>Form of Amended and Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.8 to Amendment No. 2 to the registrant's registration statement on Form S-1 (File No. 333-130759) on March 17, 2006 and incorporated herein by reference).</u>
3.2	<u>Amended and Restated Bylaws of the registrant, as amended and restated on October 2, 2024 (filed as Exhibit 3.1 to the registrant's current report on Form 8-K (File No. 001-34186) on October 3, 2024 and incorporated herein by reference).</u>
3.3	<u>Amended and Restated Certificate of Designation of Rights, Preferences and Privileges of Series A Junior Participating Preferred Stock of Vanda Pharmaceuticals Inc. (filed as Exhibit 3.1 to the registrant's current report on Form 8-K (File No. 001-34186) on April 17, 2024 and incorporated herein by reference).</u>
10.1*	<u>Amendment No. 8 to Lease, dated as of May 1, 2026, by and between Square 54 Office Owner LLC and Vanda Pharmaceuticals Inc. (filed herewith).</u>
31.1*	<u>Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2*	<u>Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1**	<u>Certification of the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), as required by Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101	The following financial information from this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL) and filed electronically herewith: (i) Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025; (ii) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025; (iii) Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2026 and 2025; (iv) Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended June 30, 2026 and 2025; (v) Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025; and (vi) Notes to Condensed Consolidated Financial Statements.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
*	Filed herewith.
**	Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Vanda Pharmaceuticals Inc.

August 6, 2026

/s/ Mihael H. Polymeropoulos, M.D.

Mihael H. Polymeropoulos, M.D.
President, Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)

August 6, 2026

/s/ Kevin Moran

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)

AMENDMENT NO. 8 TO LEASE

THIS AMENDMENT NO. 8 TO LEASE (“**Amendment No. 8**”) is made as of 5/1/2026 (“**Effective Date**”), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (“**Landlord**”), and VANDA PHARMACEUTICALS INC., a Delaware corporation (“**Tenant**”).

WITNESSETH:

WHEREAS, by Lease dated as of July 25, 2011 (the “**Initial Lease**”), as amended by that Amendment No. 1 to Lease dated as of March 18, 2014 (“**Amendment No. 1**”), and that Amendment No. 2 to Lease dated as of June 20, 2016 (“**Amendment No. 2**”), and that Amendment No. 3 to Lease dated as of March 28, 2018 (“**Amendment No. 3**”), and that Amendment No. 4 to Lease dated as of March 29, 2018 (“**Amendment No. 4**”), and that Amendment No. 5 to Lease dated as of April 11, 2019 (“**Amendment No. 5**”), and that Amendment No. 6 to Lease dated as of May 7, 2020 (“**Amendment No. 6**”), and that Amendment No. 7 to Lease dated June 24, 2025 (“**Amendment No. 7**”) (the Initial Lease, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, and Amendment No. 7 collectively, the “**Lease**”), Landlord is leasing to Tenant 43,462 square feet of rentable area (the “**Current Premises**”) located in the East Tower of the building located at 2200 Pennsylvania Avenue, N.W., Washington, D.C. (the “**Building**”); and

WHEREAS, the Lease Term for the Current Premises is scheduled to expire on July 31, 2028.

WHEREAS, pursuant to Landlord’s rights under Amendment No. 7, Landlord exercised its option to accelerate the termination of the 9,928 square feet of rentable area situated on the fifth (5th) floor of the East Tower of the Building (“**Amendment No. 7 Expansion Space**”) via delivery of written notice to Tenant on March 23, 2026 (“**Early Termination Notice**”).

WHEREAS, Landlord and Tenant desire to amend the Lease (i) to provide for the expansion of the Current Premises to include certain additional space containing approximately 6,845 square feet of rentable area situated on the sixth (6th) floor of the East Tower of the Building, which space is described on Exhibit A-1 attached hereto (“**Amendment No. 8 Expansion Space**”), (ii) to extend the Lease Term, (iii) to confirm the accelerated expiration of the Lease with respect to the Amendment No. 7 Expansion Space, and (iv) to make certain other amendments to the Lease, all as more particularly set forth in this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants and premises contained herein and other good and valuable consideration the receipt and sufficiency of which hereby are acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows:

1. Defined Terms. All capitalized terms used herein and not otherwise defined herein shall have the same meanings as provided for such terms in the Lease.

2. Amendment No. 8 Expansion Space.

(a) Landlord hereby leases the Amendment No. 8 Expansion Space to Tenant, and Tenant hereby leases the Amendment No. 8 Expansion Space from Landlord, for a term beginning on the Amendment No. 8 Expansion Space Delivery Date (as defined in Paragraph 7 below) and continuing through the expiration of the Lease Term and any extension thereof (*i.e.*, the Lease Term for the Amendment No. 8 Expansion Space will be coterminous with the Lease Term for the Current Premises, as extended pursuant to Paragraph 4(a) below). Beginning on the Amendment No. 8 Expansion Space Delivery Date, the Premises shall be deemed to include the Amendment No. 8 Expansion Space.

3. Early Expiration of Amendment No. 7 Expansion Space. Notwithstanding anything to the contrary in the Lease or the Early Termination Notice, the Lease Term with respect to the Amendment No. 7 Expansion Space shall automatically expire on November 30, 2026 (and not December 1, 2026). As the Effective Date of this Amendment No. 8, the term “**Early Termination Date**” shall mean November 30, 2026. Tenant shall surrender the Amendment No. 7 Expansion Space to Landlord on or before the Early Termination Date in the condition required under the Lease, including all obligations relating to surrender and restoration. For avoidance of doubt, commencing on December 1, 2026, all references in the Lease to the “Premises” shall be deemed to mean an aggregate of 40,379 square feet consisting of the sum of (A) the Renewal Premises equal to 33,534 square feet consisting of the following areas: (i) the 21,400 square feet of rentable area located on the third (3rd) floor of the East Tower of the Building, and (ii) the 12,134 square feet of rentable area located on the second (2nd) floor of the East Tower of the Building, *plus* (B) the Amendment No. 8 Expansion Space consisting of 6,845 square feet of rentable area situated on the sixth (6th) floor of the East Tower of the Building.

4. Lease Term.

(a) The Lease Term for the Renewal Premises and the Amendment No. 8 Expansion Space is hereby extended for a period (the “**Renewal Term**”) commencing on August 1, 2028 (the “**Renewal Commencement Date**”) upon and subject to the same terms, covenants and conditions as in the Existing Lease, except as otherwise set forth in this Amendment, and expiring on July 31, 2038 (the “**Renewal Expiration Date**”), unless earlier terminated or extended pursuant to the terms of the Lease.

(b) Tenant shall maintain the right to extend the term of the Lease for the entire Premises provided in Rider No. 1 to the Initial Lease, as modified by this Amendment, effective upon the Renewal Expiration Date. The parties acknowledge and agree that, except as set forth in this Paragraph 4, Tenant has no other right or option to renew or extend the Lease Term beyond the Renewal Expiration Date.

(c) All other terms and conditions of the Renewal Term shall be in accordance with Rider No. 1 to the Lease; provided however, the first sentence of Section 1(a) of Rider No. 1 to Lease shall be amended to read as follows:

“1. (a) Tenant shall exercise its right of renewal with respect to the Renewal Term by giving Landlord written notice of the exercise thereof (“**Renewal Option Notice**”) not less than twelve (12) months (“**Outside Notice Deadline**”) and not more than fourteen (14) months prior to the Renewal Expiration Date (as defined in Amendment No. 8).”

5. Annual Base Rent.

(a) Tenant shall continue to pay annual base rent to Landlord for the Current Premises, net of all Operating Expenses, without set off, deduction or demand, at the applicable rate(s) set forth in the Lease through July 31, 2028; it being agreed and acknowledged that the Lease Term with respect to the Amendment No. 7 Expansion Space shall automatically expire on November 30, 2026, and Tenant shall have no additional rental obligations for the Amendment No. 7 Expansion Space on and after December 1, 2026.

(b) Subject to Paragraph 5(c) below, commencing on December 1, 2026 and continuing through to July 31, 2028, Tenant shall pay to Landlord as annual base rent for the Amendment No. 8 Expansion Space, net of all Operating Expenses, without set off, deduction or demand, as follows:

Period	Annual Base Rent per RSF	Annual Base Rent	Monthly Installment of Annual Base Rent
12/1/2026 – 11/30/2027	\$61.00	\$417,545.04	\$34,795.42
12/1/2027 – 7/31/2028	\$62.53	\$428,017.80*	\$35,668.15

*On an annualized basis

(c) Notwithstanding anything to the contrary contained in this Paragraph 5 and provided no Event of Default by Tenant has occurred, Landlord hereby agrees to grant Tenant an abatement of the annual base rent payable hereunder (and the Operating Expenses payable pursuant to Paragraph 6 below) for the Amendment No. 8 Expansion Space for a period of eleven (11) full calendar months commencing December 1, 2026 and continuing through October 31, 2027. Thereafter, Tenant shall pay the full amount of annual base rent due for the Amendment No. 8 Expansion Space in accordance with the provisions of this Paragraph 5 and Article III of the Initial Lease (and the full amount of Tenant's proportionate share of Operating Expenses due in accordance with the provisions of Paragraph 6 below and Article IV of the Initial Lease).

(d) Subject to Paragraph 5(e) below, commencing on August 1, 2028, Tenant shall pay to Landlord as annual base rent for the then Premises (i.e, consisting of the Renewal Premises and the Amendment No. 8 Expansion Space), net of all Operating Expenses, without set off, deduction or demand, as follows:

Period	Annual Base Rent per RSF	Annual Base Rent	Monthly Installment of Annual Base Rent
8/1/2028 – 7/31/2029	\$64.00	\$2,584,256.04	\$215,354.67
8/1/2029 – 7/31/2030	\$65.60	\$2,648,862.36	\$220,738.53
8/1/2030 – 7/31/2031	\$67.24	\$2,715,084.00	\$226,257.00
8/1/2031 – 7/31/2032	\$68.92	\$2,782,920.72	\$231,910.06
8/1/2032 – 7/31/2033	\$70.64	\$2,852,372.52	\$237,697.71
8/1/2033 – 7/31/2034	\$72.41	\$2,923,843.44	\$243,653.62
8/1/2034 – 7/31/2035	\$74.22	\$2,996,929.44	\$249,744.12
8/1/2035 – 7/31/2036	\$76.08	\$3,072,034.32	\$256,002.86
8/1/2036 – 7/31/2037	\$77.98	\$3,148,754.40	\$262,396.20
8/1/2037 – 7/31/2038	\$79.93	\$3,227,493.48	\$268,957.79

(e) Notwithstanding anything to the contrary contained in this Paragraph 5 and provided no Event of Default by Tenant has occurred, Landlord hereby agrees to grant Tenant an abatement of the annual base rent payable hereunder (and the Operating Expenses payable pursuant to Paragraph 6 below) for the Renewal Premises for a period of eleven (11) full calendar months commencing on August 1, 2028, and continuing through June 30, 2029. Thereafter, Tenant shall pay the full amount of annual base rent due for the Renewal Premises in accordance with the provisions of this Paragraph 5 and Article III of the Initial Lease (and the full amount of Tenant's proportionate share of Operating Expenses due in accordance with the provisions of Paragraph 6 below and Article IV of the Initial Lease).

6. Operating Expenses. Except as set forth in Paragraph 5(c) and Paragraph 5(e) above, commencing on December 1, 2026 and continuing thereafter during the Lease Term, Tenant shall pay to Landlord Tenant's proportionate share of Operating Expenses for the Amendment No. 8 Expansion Space and the Renewal Premises, without set off, deduction or demand, through the expiration of the Lease Term (as extended pursuant to Paragraph 4(a) above).

7. As-Is Condition. Landlord shall deliver the Amendment No. 8 Expansion Space to Tenant on or before the date that is two (2) business days after the Effective Date (such date of delivery, the "**Amendment No. 8 Expansion Space Delivery Date**"), and Tenant hereby accepts the Amendment No. 8 Expansion Space in its "as is" condition as of the Amendment No. 8 Expansion Space Delivery Date. Landlord is under no obligation to make any alterations or improvements in or to any part of the Amendment No. 8 Expansion Space in connection with Tenant's leasing thereof or, other than the Renewal Allowance and the Expansion Allowance (each, as defined in Exhibit B hereto), to pay any allowance with respect to Alterations to be made by Tenant therein. Tenant shall make certain improvements to the Renewal Premises and the Amendment No. 8 Expansion Space as more particularly described in Exhibit B. Notwithstanding the foregoing, Landlord shall be responsible for the cost and expense of demising the Amendment No. 8 Expansion Space from the remaining space on the 6th floor and finishing the interior side of the demising walls ready for paint ("**6th Floor Demising Work**"). The parties acknowledge that Landlord will, at Landlord's sole cost and expense, construct a new common corridor on the 6th Floor in connection with the aforementioned demising work ("**Landlord's 6th Floor Corridor Work**"). Landlord and Tenant shall each include the location of the demising walls on their respective plans for 6th floor work. Tenant shall request an itemized break-out of the costs for the 6th Floor Demising Work from its Leasehold Contractor. Landlord and Tenant shall keep each other informed of the schedules for their respective work on the 6th floor. If Tenant is ready to start the Expansion Leasehold Work on the 6th floor prior to Landlord being ready to start Landlord's 6th Floor Corridor Work, Tenant shall perform the 6th Floor Demising Work and Landlord shall reimburse Tenant for the cost thereof following Landlord's receipt of written request from Tenant including copies of paid invoices and other reasonable evidence as Landlord may request. If Landlord is ready to start Landlord's 6th Floor Corridor Work on the 6th floor prior to Tenant being ready to start the Expansion Space Leasehold Work on the 6th floor, Landlord, at its sole cost, shall perform the 6th Floor Demising Work. Landlord and Tenant shall (and shall cause their respective contractors to) coordinate the performance of the Expansion Space Leasehold Work, Landlord's 6th Floor Corridor Work and the 6th Floor Demising Work on the 6th floor, as applicable.

8. Right of First Offer. Subject to the Superior Rights (as defined below), Landlord hereby grants to Tenant the right to lease the additional office space located on the 6th floor of East Tower of the Building as shown on Exhibit A-2, as it becomes available and is offered to the general public following the initial leasing of the space (the "**ROFO Space**") in accordance with the following terms and

conditions. Notwithstanding the foregoing, with respect to any ROFO Space that is anticipated to become available during the last 36 months of the initial Lease Term but prior to the deadline for delivery to Landlord of Tenant's Renewal Option Notice pursuant to Rider No. 1 (i.e., solely in the event Tenant has the right to exercise such renewal option and the deadline therefor has not occurred), Tenant may lease such ROFO Space only in the event that Tenant irrevocably elects to exercise such renewal option by delivering to Landlord Tenant's Renewal Option Notice concurrently with Tenant's ROFO Election Notice (hereinafter defined) to lease such ROFO Space; otherwise Tenant shall have no right to lease any ROFO Space that is anticipated to become available during the last 36 months of the Lease Term.

(a) Subject to the Superior Rights (as defined below), before leasing the ROFO Space to a third party (that is not a holder of any Superior Rights), Landlord shall notify Tenant of the availability of the ROFO Space ("**Landlord's ROFO Notice**") including (i) a description of such ROFO Space, (ii) the anticipated delivery date for such ROFO Space (the "**Anticipated ROFO Space Delivery Date**"), and (iii) Landlord's proposed fair market rent (including applicable concessions) and any security required for the lease of such ROFO Space.

(b) Tenant will have a period of 5 business days following receipt of Landlord's ROFO Notice to notify Landlord in writing ("**Tenant's ROFO Election Notice**") that Tenant desires to lease such ROFO Space, which election shall be irrevocable by Tenant. The term and rent for such ROFO Space shall commence on the date on which Landlord delivers such ROFO Space to Tenant in the as-is condition thereof as of the date of delivery, and shall be coterminous with the Lease Term applicable to the remainder of the Premises. Tenant shall lease such ROFO Space upon and subject to all the same terms and conditions as Tenant's leasing of the Premises, except that the leasing of such ROFO Space shall be for a rental equal to 100% of the then prevailing fair market rate and applicable concessions (for a new lease, instead of a renewal, taking into account the remaining Lease Term applicable with respect to such ROFO Space), as determined pursuant to the applicable provisions of Rider No. 1 attached to the Lease. Except as otherwise expressly provided in this Paragraph 8, all other terms and conditions of the Lease shall apply to such ROFO Space, expressly excluding the base rent and additional rent abatement granted in this Amendment No. 8, any other express abatements provided in the Lease, and any obligation for Landlord to pay for or perform the Leasehold Work or any other alterations, improvements and allowances for such ROFO Space.

(c) In the event Tenant notifies Landlord in writing prior to the deadline for Tenant's ROFO Election Notice that Tenant does not desire to lease the applicable ROFO Space or Tenant does not timely provide to Landlord Tenant's ROFO Election Notice, Tenant shall have no further right hereunder to lease the ROFO Space that was the subject of Landlord's ROFO Notice.

(d) If Tenant leases any ROFO Space hereunder, Landlord shall deliver possession of such ROFO Space to Tenant promptly after the date on which the ROFO Space is vacated by the prior tenant thereof. Landlord shall incur no liability, and the expiration date of the term for the ROFO Space shall not be extended, if Landlord is unable to deliver possession of the ROFO Space to Tenant on the Anticipated ROFO Space Delivery Date due to any holdover tenant's refusal to vacate, or for any other reason beyond Landlord's reasonable control. Landlord agrees to use commercially reasonable efforts to obtain possession of such ROFO Space as soon as reasonably possible (including instituting eviction proceedings).

(e) If an Event of Default by Tenant exists under the Lease at the time of Tenant's ROFO Election Notice or at any time prior to the date on which the ROFO Space is delivered to Tenant, at Landlord's election Tenant shall have no right to lease such ROFO Space.

(f) Tenant's right to lease the ROFO Space hereunder shall be applicable solely with respect to the entire parcel of ROFO Space offered to Tenant in Landlord's ROFO Notice. Tenant shall have no right whatsoever to lease less or more than the entire amount of ROFO Space set forth in Landlord's ROFO Notice.

(g) Promptly after Tenant elects in writing to lease the ROFO Space hereunder, the parties shall execute an amendment to the Lease (reasonably acceptable to Landlord and Tenant) adding such space to the Premises on the terms and conditions specified herein. Any failure of the parties to execute such an amendment shall not affect the validity of the leasing of any such ROFO Space in accordance with the terms and conditions of this Paragraph 8.

(h) Tenant's rights under this Paragraph 8 are personal to and may be exercised only by the initial named Tenant under the Lease ("**Initial Tenant**") and may not be exercisable by any assignee or subtenant of Initial Tenant except an assignee that is a Permitted Transferee with respect to an assignment of the entire Premises that constitutes a Permitted Transfer pursuant to Section 7.4 of the Lease.

(i) At Landlord's election, Tenant's rights under this Paragraph 8 shall lapse and be of no further force or effect, if, at the time Tenant would otherwise be entitled to exercise its expansion rights (or at any time thereafter prior to the delivery of the ROFO Space), Tenant (including any Permitted Transferee) is leasing less than 100% of the Premises leased as of the Effective Date or subleasing more than 20% of the Premises leased as of December 1, 2026.

(j) Notwithstanding anything in this Paragraph 8 to the contrary, Tenant's rights hereunder are subject and subordinate to the right of Hunton & Williams LLP (and its successors and assigns, as applicable "**HW**") to expand into the ROFO Space, pursuant to expansion rights (including rights to first offer space) contained in the HW lease (collectively, the "**Superior Rights**").

9. Security Deposit. As of the Effective Date, Landlord is holding a Security Deposit equal to an aggregate amount of \$349,000.00, which Security Deposit is in the form of 3 Letters of Credit. Notwithstanding anything in the Lease to the contrary, Tenant shall maintain a Security Deposit in the total amount of \$349,000.00 throughout the Renewal Term. Within 30 days of the Effective Date, Tenant shall cause each of the 3 Letters of Credit to be extended to October 29, 2038 (i.e. the 90th day after the Renewal Expiration Date, as required pursuant to Article V). Any right of Tenant to reduce the Security Deposit is hereby deleted and of no further force or effect.

10. Ratification. Except as otherwise expressly modified by the terms of this Amendment No. 8, the Lease shall remain unchanged and continue in full force and effect. All terms, covenants and conditions of the Lease not expressly modified herein are hereby confirmed and ratified and remain in full force and effect, and, as further amended hereby, constitute valid and binding obligations of Landlord and Tenant enforceable according to the terms thereof.

11. Broker. Landlord and Tenant each represent and warrant to the other that neither of them has employed or dealt with any broker, agent or finder in carrying on the negotiations relating to this

Amendment No. 8, other than Savills Inc. (“**Broker**”), and each party shall indemnify and hold the other harmless from and against any claim or claims for brokerage or other commissions asserted by any broker, agent or finder engaged by Landlord or Tenant or with whom Landlord or Tenant has dealt in connection with this Amendment No. 8.

12. Authority.

(a) Tenant hereby represents and warrants to Landlord that Tenant is a duly organized and existing corporation and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary corporate action has been taken to enter into this Amendment No. 8 and that the person signing this Amendment No. 8 on behalf of Tenant has been duly authorized to do so.

(b) Landlord hereby represents and warrants to Tenant that Landlord is a duly organized and existing limited liability company and is in good standing under the laws of the State of Delaware and the District of Columbia, that all necessary company action has been taken to enter into this Amendment No. 8 and that the person signing this Amendment No. 8 on behalf of Landlord has been duly authorized to do so.

13. Landlord and Tenant Representations and Acknowledgements.

(a) To the best of Tenant’s knowledge, Landlord has performed all of its obligations under the Lease. To the best of Tenant’s knowledge, Landlord is not in default under the Lease as of the date hereof, and Tenant is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Landlord under the Lease. Tenant has no current claims, defenses or set-offs of any kind to the payment or performance of Tenant’s obligations under the Lease. Nothing contained herein shall be deemed to waive any sums due from Tenant to Landlord, or any default or event which, with the passage of time or delivery of notice, or both, would constitute a default by Tenant under the Lease as of the date hereof.

(b) To the best of Landlord’s knowledge, Tenant has performed all of its obligations under the Lease. To the best of Landlord’s knowledge, Tenant is not in default under the Lease as of the date hereof, and Landlord is unaware of any condition or circumstance which, but for the passage of time or delivery of notice, or both, would constitute an event of default by Tenant under the Lease. Landlord has no current claims, defenses or set-offs of any kind to the payment or performance of Landlord’s obligations under the Lease. Nothing contained herein shall be deemed to waive any sums due from Landlord to Tenant, or any default or event which, with the passage of time or delivery of notice, or both, would constitute a default by Landlord under the Lease as of the date hereof.

14. Mutual Negotiation. Landlord and Tenant each hereby covenants and agrees that each and every provision of this Amendment No. 8 has been jointly and mutually negotiated and authorized by both Landlord and Tenant, and in the event of any dispute arising out of any provision of this Amendment No. 8, Landlord and Tenant each does hereby waive any claim of authorship against the other party.

15. General Provisions. Landlord and Tenant agree that the terms and conditions of this Amendment No. 8 shall also be subject to the same provisions regarding confidentiality as are contained within Section 25.20 of the Initial Lease. This Amendment No. 8 may be executed in multiple counterparts, each of which shall be an original, but all of which shall constitute one and the same

Amendment No. 8. The parties may conduct this transaction by electronic means and this Amendment No. 8 may be executed by electronic signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature. Without limitation, “electronic signature” shall include digital execution through a provider reasonably acceptable to Landlord, faxed versions of an original signature or electronically scanned and transmitted versions (e.g., via PDF) of an original signature.

16. Binding Effect. This Amendment No. 8 shall not be effective and binding unless and until fully executed and delivered by each of the parties hereto. All of the covenants contained in this Amendment No. 8, including, but not limited to, all covenants of the Lease as modified hereby, shall be binding upon and inure to the benefit of the parties hereto, their respective heirs, legal representatives, and permitted successors and assigns.

[REMAINDER OF PAGE INTENTIONALLY BLANK. SIGNATURE PAGE FOLLOWS.]

IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment No. 8 to Lease as of the date and year first above written.

LANDLORD:

SQUARE 54 OFFICE OWNER LLC,
a Delaware limited liability company

By: BP/DC PROPERTIES, INC.,
a Maryland corporation, its sole member and manager

By: /s/ John J. Stroman
Name: John J. Stroman
Title: EVP, Co-Head of the Washington, DC Region

TENANT:

VANDA PHARMACEUTICALS INC.,
a Delaware corporation


By: /s/ Mihael H. Polymeropoulos
Name: Mihael H. Polymeropoulos
Title: Chief Executive Officer

EXHIBIT A-1
DIAGRAM OF AMENDMENT NO. 8 EXPANSION SPACE



2200 Pennsylvania Avenue NW
Vanda Pharmaceuticals Amendment No. 8

EXHIBIT A-2 DIAGRAM OF ROFO SPACE



**CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Mihael H. Polymeropoulos, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 6, 2026

/s/ Mihael H. Polymeropoulos, M.D.

Mihael H. Polymeropoulos, M.D.
President, Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin Moran, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

August 6, 2026

/s/ Kevin Moran

Kevin Moran

**Senior Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)**

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc. (the Company), does hereby certify, to the best of such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the Form 10-Q) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.

August 6, 2026

/s/ Mihael H. Polymeropoulos, M.D.

Mihael H. Polymeropoulos, M.D.
President, Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)

August 6, 2026

/s/ Kevin Moran

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification "accompanies" the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.